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ABSTRACT 
Danielle L. Jacobs 
Progress towards the Total Synthesis of Pyranicin 
(Under the direction of Michael T. Crimmins) 
 
Progress towards the total synthesis of pyrancin, a structurally-unique member of 
the annonaceous acetogenin family of natural products, is reported.  Methodology 
includes an asymmetric glycolate aldol reaction and an asymmetric glycolate 
alkylation to install key stereocenters in the natural product.  Several strategies 
towards uniting the pyranicin skeletal backbone are evaluated. 
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CHAPTER 1 
BIOLOGICAL AND STRUCTURAL ASPECTS OF ANNONACEOUS ACETOGENIN 
NATURAL PRODUCTS 
 
The discovery of the unique structure and remarkable antileukemic activity of 
uvaricin, isolated in 19821 from the plant species Uvari accuminata, has incited a 
vast amount of research into the activity, potency, and synthesis of the annonaceous 
acetogenin family of natural products.  In the 25 years since uvaricin’s discovery, 
more than 400 natural products of the Annonaceae family have been identified, and 
their total syntheses have flooded the literature for the past decade.2  These 35- or 
37-carbon fatty acid-derived natural products are typically characterized by long 
aliphatic chains bearing a terminal γ-methylbutenolide, yet differ in the placement 
and structure of oxygenated moieties along these chains.  For example, while most 
acetogenins possess tetrahydrofuran (THF) rings, pyranicin (1), isolated in 1997 by 
McLaughlin and coworkers3 from the stem bark of the Goniothalamus giganteus tree 
native to Thailand, is one of only two known acetogenins to bear solely a 
tetrahydropyran (THP) ring. 
 
Its discovery has thus allowed for further insight into the biogenesis and 
structure-activity relationships (SAR) of this family of natural products. 
A. Biological Activity of Annonaceous Acetogenins 
Research into the biological activity of the annonaceous acetogenin natural 
products has characterized them as promising anti-feedant and pesticide treatments, 
as well as anti-malarial, anti-parasitic, and anti-tumor drugs, and they have even 
exhibited promising results against Parkinsonism.4  In 2007, due to the enhanced 
accessibility to annonaceous acetogenins via total synthesis, Takahashi and 
Yonezawa were able to unfold the in vivo cytotoxicity (ID50 = 9.4 µM)5  of pyranicin 
against the growth of promyelocytic leukemia cells (HL-60).  The authors attribute 
this high cytotoxicity to pyranicin’s ability to block DNA polymerase in the cancerous 
cells, which is necessary to initiate DNA replication. 
Furthermore, annonaceous acetogenins have been classified as the most 
powerful inhibitors of mitochondrial Complex I (NADH-ubiquinone oxidoreductase) in 
both mammalian and insect electron transport systems (Figure 1).6,7  Despite the 
limited knowledge of the structure of Complex I,8 it has been proposed that 
acetogenins interrupt the final electron transfer from NADH to ubiquinone,6,9-12 which 
is essential for ATP production. The resulting decrease in cellular ATP could then 
lead to cell death by apoptosis.  Pyranicin, in particular, demonstrates selective in 
vitro cytotoxicity (ED50 of 10-2 µg/mL) against human pancreatic adenocarcinomal 
cell lines (PACA-2).3,13 
 
2 
 
 Figure 1.11 Schematic representation of oxidative phosphorylation electron 
transport system. 
These two vastly different mechanisms of inhibition, the ability to block both 
DNA replication and electron transfer in completely different systems, make 
pyranicin a good candidate as a chemotherapeutic. 
Bioactivity assays on the annonaceous acetogenins as well as their 
derivatives, analogs, and mimics over the past decade have elucidated some 
aspects of the biological mechanism.  The manner in which the common acetogenin 
backbone interacts with Complex I remains a mystery, but three plausible 
possibilities have prevailed.  The natural product could inhibit the enzyme’s normal 
                                                
1 Taken from Matsuno-Yagi, A.; Yagi, T. J. Bioenerg. Biomemb. 2001, 33, 155. 
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function by 1) directly interacting with and blocking the ubiquinone binding site, 2) 
inducing a dynamic conformational change to the membrane protein that renders it 
dormant, or 3) binding to a large inhibitor binding pocket, separate from the 
ubiquinone reduction site, within the membrane protein.14   
B. SAR of Annonaceous Acetogenins 
The highly conserved skeletal backbone of the Annonaceae natural products 
can be dissected into four structural elements, all of which have been thoroughly 
investigated into their effect on bioactivity: 1) terminal butenolide, 2) hydrophobic 
alkyl spacer, 3) hydrophilic ring(s) with flanking hydroxyl groups, and 4) long 
hydrophobic carbon chain. 
1. Terminal butenolide 
It has long been known that the highly conserved terminal γ-methylbutenolide 
unique to this family of natural products is crucial to their observed bioactivity.  
However, the vast structural difference between the acetogenins and the other well-
known ubiquinone oxidoreductase inhibitors piericidin A and rotenone,15 leaves the 
question as to how this common structural feature actually interacts with the 
membrane protein.  In order to investigate its role in inhibiting electron transfer to 
ubiquinone in Complex I, acetogenin derivatives bearing a quinone moiety in place 
of the butenolide ring were recently synthesized by Koert,16 Miyoshi,17 and 
Poupon,18 who predicted that the butenolide subunit may bind competitively at the 
quinone binding site of Complex I.  All three groups found that quinone-substituted 
mucocin, bullatacin, and squamocin all exhibit equal Complex I inhibitory activity as 
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their parent natural butenolide relatives.  However, the increased reduction potential 
of butenolide (E = -2.69V) in comparison to quinone (E = -0.75V), which would make 
electron transfer more likely to occur, makes the mechanism of inhibition unlikely to 
be mere competitive docking by the butenolide ring.16  Instead, it is believed that 
butenolide interrupts the necessary electron transfer through either blocking the 
active binding site, or invoking an allosteric effect in the enzyme itself.17 
2. Hydrophobic alkyl spacer 
By varying the the length between the oxygenated rings and the butenolide of 
several bullatacin analogs, it was revealed that linkers bearing 11-13 carbons exhibit 
the greatest inhibition against bovine heart mitochondrial Complex I.12,19,20  Inhibition 
using derivatives with longer carbon chains is decreased immensely,21 further 
supporting that the length of the chain may help govern an optimal conformation of 
the natural product to affect inhibition.   
3. Hydrophilic ring(s) with flanking hydroxyl groups 
The oxygen-containing ring(s) and their respective flanking hydroxyl groups 
were originally proposed to behave as hydrophilic anchors in the lipid bilayer that 
could hydrogen bond with the hydrophilic mitochondrial membrane, carrying the γ-
methylbutenolide to its target.6,13  More recent studies suggest, however, that when 
the γ-methylbutenolide is removed, the bioactivity of the poly-oxygenated species is 
somewhat maintained.22  For example, some NMR studies reveal that the 
oxygenated moieties behave as an ionophore, wherein the acetogenins sequester 
endogenous cations (Ca2+, Na+, Fen+) and adopt a spatial conformation different 
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from the normal resting state.23-27  This is further supported by the observation that 
acetogenins with free hydroxyl moieties display higher bioactivity than their 
respective oxidized and protected relatives.28  Although sequestration may shut 
down normal enzyme activity, it is more likely that the resultant conformational 
change is responsible for the observed inhibitory activity.  Alternatively, it is also 
possible that the hydrophilic nature of the rings and their adjacent hydroxyl moieties 
merely create an optimal hydrophilic environment that forces the adoption of an 
active conformation that can inhibit the enzyme binding site.20,29  In general, the 
number, identity, and stereochemistry of these rings do not directly affect their 
bioactivity.12,19,30,31 
The design and synthesis of acetogenin mimics have also helped elucidate 
the role of oxygenation on these natural products, and supports the ionophoric role 
of the polyoxygenated chain.  By eliminating the ethylene bridge of the rings in some 
bis-tetrahydrofuran-containing natural products, most notably ethylene glycol mimics 
of uvaricin,32 corossolone and corossolin,33 and bullatacin (2),34-36 Wu and coworkers 
observed identical, if not increased, potency of linear mimics versus their cyclic 
analogues against several human cancer cell lines (Figure 1.2).  These, among 
others,37-39 support not only the important role of oxygenation to the remarkable 
bioactivity of annonaceous acetogenins, but also demonstrate that less complex 
derivatives exhibiting the same cytotoxic potential could be synthesized faster, in a 
more efficient and economical fashion. 
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 Figure 1.2 Designed ethylene glycol mimic of bullatacin (2).34 
4. Long hydrophobic carbon chain 
The long hydrophobic chain common to the western fragment of the 
acetogenins does not directly appear to be crucial to the bioactivity of acetogenins.40  
However it has been shown that acetogenins that contain between 35 and 37 
carbons exhibit higher potency than their shorter and longer cousins.13 
All of these findings support recent studies on the relationship between 
acetogenin conformation and their corresponding inhibitory action against HL-60.  
Energy minimization and charge density calculations of both classical and non-
classical acetogenins reveal a common V-shape (Figure 1.3),41  wherein the 
hydrophilic rings and adjacent hydroxyl groups are fixed at the vertex (although 
longer acetogenins tend to adopt a sickle shape, which is further accompanied by 
decreased bioactivity).6 
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 Figure 1.32 Graphic stick models of various acetogenins.  Carbon atoms are 
represented in green, hydrogen atoms in white, and oxygen atoms in red.  Yellow 
arrow (a) denotes molecular length, and (b) denotes molecular width.  Acetogenins 
represented: (1) mucocin, (2) jimenizin, (3) 19-epi-jimenizen, (4) muconin, (5) 
pyranicin, (6) pyragonicin, (7) 10-epi-pyragonicin, (8) 3-hydroxy-4-methyl-2-
tetradecyl-4-butanolide. 
The combination of all of these structural features appear to influence the 
length and width of the natural product,41 perhaps by fixing them into an optimal 
conformation that minimizes hydrophobic interactions (Figure 1.3).  For example, 
                                                
2 Taken from Ishimaru, C.; Takeuchi, T.; Yonezawa, Y.; Kuriyama, I.; Takemura, M.; Kato, I.; 
Sugawara, F.; Yoshida, H.; Mizushina, Y. Lett. Drug Design Discovery 2007, 4, 239. 
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the greatly enhanced bioactivity of pyranicin, which displays a moderate length and 
width, against HL-60 when compared to the seven other acetogenins, suggests that 
the inhibitor binding site may be best suited for natural products that span a specific 
area, as well as possess a finely tuned mixture of hydrophobicity and hydrophilicity 
to match that of the binding pocket.   
C. Biosynthesis and Biomimetic Approaches to Annonaceous Acetogenins 
The recurrent structural features common to all the members of the 
Annonaceae family of natural products have shed light on their biosynthetic 
evolution.  The preserved 35-and 37-carbon skeletons suggest that annonaceous 
acetogenins naturally arise from laceroic (C-32) and ghedoic (C-34) fatty acids via a 
polyketide pathway.  Site selective dehydrogenation to form the polyene, followed by 
enzymatic oxidation to the polyepoxide and cyclization to the respective polyether 
provides the acetogenin carbon skeleton.27,42  The γ-methylbutenolide is further 
proposed to be introduced via an aldol-type reaction with a three-carbon fragment, 
common for fatty acid-derived molecules,.43  The isolation of non-cyclic and epoxide-
containing annonaceous acetogenins supports this biosynthetic postulate, as does 
the facile construction of additional THF rings from muridienins and 
chatenaytrienans, which are naturally-occuring polyene mono- and bis-THF 
acetogenin precursors.42,44 
The first synthetic approach to a poly-oxygenated acetogenin backbone, 
accomplished by Hoye and coworkers in 1985, was a biomimetic approach that lent 
support to the biosynthetic proposal (Scheme 1.1).45,46  Triendiol 4, prepared in two 
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steps from (Z)-oct-4-enedial, underwent regioselective and stereoselective 
epoxidation according to Sharpless’ protocol.  The subsequent epoxidation of the 
internal olefin of bis-epoxide 5 provided triepoxide 6, which was proposed to 
undergo base-induced epoxide opening/cyclization to provide bis-tetrahydrofuran 
skeletons. 
However, Hoye found that racemic products resulted, as a result of both “top 
down” (path a, filled arrows) and “bottom up” (path b, dashed arrows) base-
promoted cyclization cascades.  Upon acetylation, tetraacetates 7 and ent-7 were 
obtained.46  However, to demonstrate that 2,5-syn-enantioenriched skeletons (9) 
could be accessed from such a biomimetic approach, the researchers later 
synthesized acetonide 8 from the intermediate bis-epoxide (5), which underwent an 
“inside out” cyclization (path c) upon acidic deprotection.  Further protection 
provided tetraacetate 9 in high regio- and diastereoselectivity.45 
This strong support for such a biosynthetic pathway paved the way for a wave 
of biomimetic approaches toward other annonaceous acetogenins,47 as well as the 
construction of chemical libraries of their stereoisomers.48,49 
A significant amount of effort has been expended towards affecting THF and 
THP ring cyclization via a one-step enzyme-mimicking oxidative cyclization.50  
Rhenium(VIII) oxide,51-54 ruthenium(VIII) oxide,55-57 and vanadium(V) oxide58 have 
efficiently accomplished this task.  This evidence provides strong support that such a 
polyketide biosynthetic pathway is facile and energetically favorable, and has paved 
10 
 
the way for fast access to a wide variety of biologically significant acetogenins and 
acetogenin analogs.48,49 
 
Scheme 1.1 Hoye’s biomimetic approach to uvaricin. 
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CHAPTER 2 
PREVIOUS SYNTHETIC APPROACHES TOWARD PYRANICIN 
 
The unique biological activity and structural backbone of pyrancin have 
prompted several approaches towards its total synthesis, particularly due to its 
limited natural bioavailability of merely 10 mg/10.7 kg of tree bark.1  These 
syntheses all divide the molecule into two key fragments: the tetrahydropyran and 
the γ-methylbutenolide. 
A. Takahashi and Nakata 
Takahashi and Nakata completed the first total synthesis of pyranicin in 
2003.2  To begin, the butenolide fragment3,4  was synthesized following a protocol 
previously employed in the laboratory’s total synthesis of mucocin.4  
Methoxyphenylmethyl (MPM)-protected aldehyde 10 underwent asymmetric 
allylation5 to provide chiral alcohol 11 (Scheme 2.1).  Following a protection-
hydroboration sequence, the resultant primary alcohol (12) was oxidized to the acid 
and immediately transformed into the corresponding methyl ester (13) in situ. 
Subsequent aldol addition with chiral aldehyde 146 provided aldol product 15 as a 
mixture of diastereomers.  Acidic removal of the tetrahydropyranyl protecting group 
further allowed for cyclization to the lactone.  After mesylation of the free alcohol and 
elimination under weakly basic conditions, the butenolide olefin was installed (16).  
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Oxidative removal of the MPM protecting group, followed by oxidation under Swern 
conditions, provided the butenolide fragment (17). 
 
Scheme 2.1 Synthesis of butenolide 10 (Takahashi and Nakata). 
The researchers envisioned closing the tetrahydropyran ring via a samarium 
iodide-mediated reductive cyclization,7 a technique previously employed in their 
synthesis of THP-containing annonaceous acetogenins4,8 as well as other natural 
products.9,10  Bidirectional chain differentiation of 2,3-O-isopropylidene-D-threitol (18, 
Scheme 2.2),11 originally reported by Kotsuki,12,13 provided hemiacetal 23, which 
following selective protection gave thioacetal 24.  Hetero-Michael addition of the free 
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alcohol to ethylpropiolate provided ethyl acrylate 25, and the ensuing radical 
cyclization yielded 2,6-syn-fused THP 26. 
 
Scheme 2.2 Synthesis of tetrahydropyran 26 (Takahashi and Nakata). 
The heightened stability of the proposed chair-like transition state of the 
reductive cyclization8 gave equatorial substituents at both C19 and C20.  The 
stereochemistry of the alcohol at C19 thus had to be inverted via a Mitsunobu 
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lactonization (Scheme 2.3).14  Ensuing reduction of lactone 27 to the lactol allowed 
for a Wittig olefination to introduce the 12-carbon chain into the western fragment of 
the molecule. 
 
Scheme 2.3 Completion of pyranicin (Takahashi and Nakata). 
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Several protecting group manipulations to THP 28 provided free primary 
alcohol 30, which was then transformed into the corresponding phosphonium iodide 
over two steps.  Aldehyde 17 was introduced, forging the THP and butenolide 
fragments via a Wittig olefination.  Hydrogenation of the internal olefin with 
Wilkinson’s catalyst, which has demonstrated tolerance to the olefin embedded in 
the γ-methylbutenolide, and subsequent deprotection under acidic conditions 
provided pyranicin (1) in 28 steps (longest linear sequence from 18). 
B. Strand and Rein 
Strand and Rein tackled their synthesis of pyranicin15 employing a 
bidirectional desymmetrization strategy developed towards the synthesis of 
polycyclic ether natural products including the annonaceous acetogenins.16    
Beginning with a common starting material (32), readily available in five steps from 
cyclohexadiene,17,18 the authors can access differentially substituted tetrahydropyran 
and tetrahydrofuran rings by varying the chiral menthol-derived phosphonate 
employed in the initial asymmetric Horner-Wadsworth-Emmons (HWE) reaction 
(Figure 2.1).19,20  After a sequence of functional and protecting group manipulations, 
giving intermediates 36 and 37, they can access various cyclic ethers via standard 
cyclization techniques, including Pd(0)-catalyzed allylic substitution,21-23 hetero-
Michael addition,24-26 and intramolecular SN2 exo-cyclization onto an epoxide. 
Bis-silyl protected dialdehyde 38 was thus carried through an asymmetric 
Still-Gennari olefination, and reduction of the aldehyde occurred with concomitant 
migration of the silyl group from the vicinal stereocenter to give stereodefined 
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Figure 2.1 Bidirectional desymmetrization strategy (Strand and Rein). 
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alcohol 39 (Scheme 2.4).  The tetrahydropyran trans-trans-substituted ring (41) was 
formed early via Mitsunobu inversion of the free alcohol followed by base-promoted 
hetero-Michael cyclization onto the (Z)-olefin.24  Similar to Takahashi and Nakata, 
the 12-carbon hydrophobic chain was installed via Wittig olefination of the 
corresponding aldehyde (42). 
 
Scheme 2.4 Synthesis of tetrahydropyran 46 (Strand and Rein). 
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Selective primary deprotection on activated alumina27 followed by oxidation 
provided aldehyde 43, which allowed for stereoselective alkynylzinc addition under 
Carreira conditions28,29 to establish the C15 stereocenter.  Protecting group 
manipulation gave terminal alkyne 45, which underwent hydrozirconation/iodination 
to give THP fragment 46, holding a vinyl iodide as a synthetic handle for further 
construction of the pyranicin backbone. 
The eastern fragment was initiated with a Still-Gennari parallel kinetic 
resolution of prochiral aldehyde 47, providing dihydropyran diastereomers 48a and 
48b (Scheme 2.5). 
 
Scheme 2.5 Parallel kinetic resolution strategy (Strand and Rein). 
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Acid-catalyzed hemiacetal formation, trapping with a second HWE reagent, 
and phosphinate ester formation gave two diastereomeric allylic phosphinate esters 
(49a and 49b), which underwent enantioconvergent Pd(0)-catalyzed allylic 
substitution to provide one diastereomer of (2-ethoxyethyl)trimethylsilyl (Teoc)-
protected allylic alcohol 50.21,22,30 
(-)-NME, Zn(OTf)2
Et3N, PhCH3, 60 °C
TMS
75%, >98:2 dr
CO2X
OH O
52
i. LDA, 14, THF, -78 °C
ii. K2CO3, MeOH
-78 °C to rt CO2X
OH O
53
OTHP
HO 1. CSA, MeOH,
2. Cl3C(O)Cl, Et3N
CH2Cl2,
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O
O
46, (PPh3)2PdCl2
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H2O, DME,
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Scheme 2.6 Synthesis of butenolide 54  and completion of pyranicin (Strand and 
Rein). 
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A three-step protocol converted the conjugated ester to the saturated 
aldehyde (51),which underwent a second Carreira alkynyl zinc addition reaction28,29 
to install the alcohol stereocenter at C15 (52, Scheme 2.6).  The γ-methylbutenolide 
was installed via an aldol/cyclization/elimination sequence analogous to that of 
Takahashi and Nakata (Scheme 2.1).  Finally, the THP and butenolide fragments 
were brought together via a Sonogashira cross-coupling reaction, and selective 
reduction of the unsaturated moieties and protecting group removal afforded the 
natural product (14 steps longest linear sequence). 
C. Makabe 
Fifteen years following their original synthesis of (-)-muricatacin (56) in 
1993,31 Makabe and coworkers elaborated the abbreviated annonaceous acetogenin 
on to pyranicin.32  Muricatacin was synthesized in a seven-step sequence from 
propargyl alcohol, employing a Sharpless epoxidation as the key step to introduce 
the asymmetry into the natural product (Scheme 2.7). 
 
Scheme 2.7 Synthesis of muricatacin 56 (Makabe). 
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Following protection of the free alcohol, the γ-lactone was reduced to the 
lactol, which underwent HWE olefination in situ to provide α,β-unsaturated ester (60, 
Scheme 2.8).  Protection and reduction provided allylic alcohol 61, and upon 
esterification with 4-biphenyl-carbonyl chloride gave aryl carbonate 62. 
 
Scheme 2.8 Synthesis of tetrahydropyran 66 (Makabe). 
The requisite tetrahydropyran ring (63) was fashioned via an intramolecular 
Pd-catalyzed allylic displacement, and the C15 alcohol stereocenter was introduced 
after an asymmetric dihydroxylation reaction (64).  A five-step sequence was then 
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followed to provide protected propargyl alcohol 66, required later to form the carbon 
framework of the natural product. 
The synthesis of the eastern fragment began with a sequence that gave 
iodide 68 from nona-1,8-diene in four steps (Scheme 2.9).  Phenylthiobutyrolactone 
(69),33 prepared in one step via the known reaction of (S)-2-methyloxirane with 
phenylthioacetic acid dianion, was introduced via an alkylation reaction,34 and 
subsequent elimination of the corresponding sulfoxide quickly provided the 
butenolide (71). 
 
Scheme 2.9 Introduction of γ-lactone 69 and completion of pyranicin (Makabe). 
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After conversion of the terminal olefin to chiral epoxide 72, the pyranicin 
backbone was united via acetylide addition of previously-prepared alkyne 66.  
Selective reduction of the resultant alkyne followed by global deprotection yielded 
pyranicin (1) in 23 steps (longest linear sequence).  Makabe’s approach clearly 
demonstrated the versatile capability for divergent syntheses of annonaceous 
acetogenins from other members of the same family of natural products.35 
D. Phillips 
Arguably the most concise approach to pyranicin to date was most recently 
achieved by Phillips and coworkers.36  The Phillips laboratory devised a concise and 
convergent total synthesis of pyranicin that brought together tetrahydropyran 
fragment 73, chiral alcohol 74, and butenolide fragment 75. The key step was an 
Achmatowicz oxidation/Kishi reduction sequence to form the tetrahydropyran ring, a 
technique Phillips had previously employed towards the norhalichondrin B 
skeleton.37   
To known furan 76, prepared in two steps from β-furylmethanol, was added 
dodecylmagnesium bromide to provide racemic furfuryl alcohol 77 (Scheme 2.10).  
Sharpless asymmetric kinetic resolution was then accomplished employing Sato’s 
conditions.38,39  The provoked epoxidation/ring-opening/lactonization sequence, first 
introduced as a racemic version by Sapp and coworkers,40 provided hemiacetal 78 
which was reduced in situ with Kishi’s reagent41 to produce syn-2,6-substituted-α,β-
unsaturated pyranone 79.  The remarkable diastereoselectivity observed in the 
reaction was attributed to the preferred axial reduction of the intermediate 
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oxacarbenium ion.  Selective reduction of the enone followed by reduction of the 
ketone gave THP alcohol 80, which was subsequently protected as its silyl ether.  
The primary benzyl alcohol was then transformed to the corresponding aldehyde 
(73) in three steps. 
 
Scheme 2.10 Synthesis of tetrahydropyran 73 (Phillips). 
Similar to the Strand and Rein’s synthesis, the C15 alcohol was 
stereoselectively installed via the Careirra asymmetric alkynylzinc addition28,29 of 
known alkyne 74,42 prepared in three steps from 4-pentynol, to aldehyde 73.5  
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Following protection as the silyl ether, the left-hand fragment of pyranicin (81) was 
completed. 
Construction of the butenolide fragment began with the addition of (S)-2-t-
butyldimethylsiloxybut-3-yne (82)43-45 to chiral epoxide 83, followed by protection of 
the resultant secondary alcohol to give alkyne 84 (Scheme 2.11).  Selective removal 
of the TBS ether provided a propargyl alcohol that was immediately converted to the 
corresponding vinyl iodide (85) under a hydroalumination/iodination protocol outlined 
by Denmark.46,47 
 
Scheme 2.11 Synthesis of butenolide and completion of pyranicin (Phillips). 
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Heck-type intramolecular acylpalladation provided an intermediate 
carboxylate which was immediately trapped by the free alcohol to give the γ-
methylbutenolide ring (86).48,49  Next, in preparation of the imminent fragment 
coupling, the PMB ether was transformed into the corresponding alkyl bromide (75). 
The pyranicin backbone (87) was hence brought together via a Suzuki cross-
coupling reaction,50 and global deprotection followed by selective hydrogenation of 
the internal alkyne gave the natural product in 13 steps longest linear sequence 
(from 76) and 10% overall yield. 
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CHAPTER 3 
ASYMMETRIC TOTAL SYNTHESIS OF PYRANCIN 
 
A. Strategies for the Preparation of Tetrahydropyran-Containing 
 Natural Products 
 
1. Common Synthetic Strategies 
The overwhelming presence of tetrahydropyran rings in bioactive natural 
products has lead to the development of a litany of synthetic strategies toward their 
stereoselective preparation.  Among the most popular manners in which to form 
these substituted heterocycles are intramolecular cyclizations onto oxacarbenium 
ions (Prins cyclization1,2) or epoxides, iodocyclizations, hetero-Diels-Alder [4+2] 
cyclizations, reduction of cyclic hemiacetals, and standard intramolecular Williamson 
ether cyclizations.3  Furthermore, the intramolecular hetero-Michael addition 
employed by Strand and Rein in their approach to pyranicin4,5 (Scheme 2.1, vide 
supra) has been widely employed to access tetrahydropyran rings in a 
stereoselective manner,3,6,7  and the radical stereoselective cyclization methodology 
developed by Nakata and Takahashi8,9 (Scheme 2.2, vide supra) is beginning to 
gain recognition in the synthetic community.3,10,11  The popularity of these two 
methodologies arises from their ability to obtain highly diastereoselective products 
via a stable six-membered chair transition state.  Furthermore, a multitude of 
palladium-catalyzed intramolecular cyclizations of hydroxyl groups onto allylic 
acetates or carbonates, such as that employed by Makabe and coworkers12 
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(Scheme 2.8, vide supra), can be found in the literature as a reliable manner 
through which tetrahydropyran rings can be formed.3 
Although these widely explored synthetic methodologies have proven 
successful towards the construction of the tetrahydropyranyl moities embedded in 
annonaceous acetogenin natural products, they fall short in their ability to affect 
facile widespread access to other polycyclic natural products with differentially-
substituted ring ethers.  Many of these cyclization strategies are only successful on 
unique substrates, or can only provide access to one ring diastereomer which may 
have to be epimerized or inverted, as seen in both Takahashi’s and Strand’s 
approaches to pyranicin.8,9  The chief challenge lies particularly in the development 
of a versatile method that can be used to access both cis and trans α,α’-
disubstituted cyclic ethers.13  Until Murai’s synthesis of obtusenyne in 199914 and 
Crimmins’ synthesis of prelaureatin and laurallene in 2000,15 no such techniques 
had been established.   
2. Crimmins’ Glycolate Aldol Methodology 
The Crimmins laboratory has since developed a powerful and versatile 
asymmetric glycolate aldol/ring-closing metathesis (RCM) strategy for the 
preparation of differentially-substituted medium-size oxygen heterocycles.  Following 
the development16 and further optimization17 of the titanium-mediated glycolate aldol 
reaction, the strategy quickly became an extensively utilized tool towards the 
synthesis of several natural products in the Crimmins laboratory including (+)-
laurencin,16 (-)-isolaurallene,18,19 and 11-acetoxy-4-deoxyasbestinin,20  as well as 
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(+)-giganticin21 and  (-)-mucocin,22 two natural products belonging to the 
annonaceous acetogenin family.  The recent development of an anti-selective 
glycolate aldol reaction23 has further expanded the utility of this synthetic strategy to 
access an even more diverse collection of substituted cyclic ethers including 
brevetoxin,24-27 a ladder polycyclic ether containing nine oxygen-containing 
heterocycles.  The attraction to such a methodology lies in the accessibility to cyclic 
ethers of varying ring size, substitution, and configuration by a mere alteration of 
reaction conditions (Figure 3.1). 
Titanium-mediated aldol reactions of glycolyloxazolidinones (Y=O) and 
glycolyloxazolidinethiones (Y=S) employing one equivalent of titanium tetrachloride 
and excess non-nucleophilic amine base affects soft enolization, which upon 
subsequent treatment with an aldehyde forms the dipole-minimized six-membered 
chair-like transition state (A).  Employing excess base or further addition of a 
coordinating ligand such as N-methylpyrrolidinone (NMP) ensures that the titanium 
metal is coordinatively saturated, so as to minimize coordination between the metal 
and the carbonyl or thiocarbonyl of the chiral auxiliary.  Evans’syn aldol adducts 
result, and subsequent removal of the chiral auxiliary, oxidation, Wittig 
methylenation, and RCM gives the desired medium-size ring ethers.  Alternatively, 
by using an excess of titanium tetrachloride and only a stoichiometric amount of 
amine base, a dipole-minimized open transition state (B) is preferred, wherein the 
excess Lewis acid coordinates to both the aldehydic and glycolate oxygens.  The 
high diastereoselectivity observed in these reactions is proposed to arise from a 
minimization of sterics by both the chiral auxiliary as well as the R’ group on the 
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aldehyde, leading to anti aldol adducts.  Thus, by following the same 
functionalization sequence as for the Evans’ syn aldol adducts, cyclic ethers with a 
different α,α’ substitution pattern can be accessed. 
 
Figure 3.1 Crimmins’ glycolate aldol strategy. 
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By analogy, it can be imagined that the high diastereoselectivities in glycolate 
aldol reactions make this methodology attractive for complex glycolate substrates 
with various stereocenters and functionalities, as has been demonstrated in the total 
syntheses of the natural products mentioned above. 
B. First Generation Approach towards Pyranicin 
Our original retrosynthesis (Figure 3.2) envisioned a convergent approach to 
pyranicin, wherein the key step would be an asymmetric alkynylzinc addition of 
alkyne 88 to aldehyde 89, fusing the pyranicin backbone while concomitantly 
installing the stereocenter at C10.  The tetrahydropyran ring would be accessed via 
an asymmetric glycolate aldol/RCM sequence, and the requisite 
glycolyloxazolidinone (91) would arise from functional group elaboration following an 
asymmetric glycolate aldol reaction between glycolate 93 and tridecanal (94).  The 
butenolide moiety would be furnished via an esterification of acrylic acid 95 with (R)-
3-buten-2-ol (96) followed by a ring-closing metathesis.  The remainder of the right-
hand fragment was predicted to be easily accessible via chain elongation of 
aldehyde 97, which would arise from an asymmetric alkylation reaction of glycolate 
98 with 2-bromo-3-iodopropene (99). 
1. Preparation of Acrylic Acid 95 
The initial strategy proposed for the butenolide fragment was modeled after 
that employed by Crimmins and She in the synthesis of giganticin, a bis-
tetrahydrofuran annonaceous acetogenin.21  Asymmetric alkylation of isopropyl-
derived glycolyloxazolidinone 98 with 2-bromo-3-iodopropene provided vinyl bromide  
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Figure 3.2 Original retrosynthetic analysis of pyranicin. 
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100 (Scheme 3.1).  Reductive removal of the chiral auxiliary to provided alcohol 
101, which was subsequently oxidized under Swern conditions.28  Chain elongation 
was affected via Wittig olefination with triphenylphosphonium salt 102, synthesized 
by reductive opening of tetrahydropyran with acetylbromide and subsequent 
exposure to triphenylphosphine and base (Scheme 3.2, Equation 1).29,30  Protection 
of the resultant primary alcohol (103) as the t-butyldimethylsilyl (TBS) ether 
furnished vinyl bromide 104. 
 
Scheme 3.1 Asymmetric glycolate alkylation and carboxylation via lithium-halogen 
exchange. 
She’s protocol21 provided precedence that lithium-halogen exchange followed 
by quenching with carbon dioxide would provide the acrylic acid necessary for 
further functionalization towards the butenolide ring. 
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In the event, however, no reaction was observed with n-butyllithium, and 
while t-butyllithium affected complete lithium-halogen exchange, the desired acrylate 
105 was obtained in only 22% yield.  The major product observed was terminal 
olefin 106, presumed to result from premature quenching of the intermediate 
vinyllithium species with water. 
Other problems existed with this synthetic route, most significantly the 
alkylation.  First, 2,3-dibromopropene (108), the precursor to the corresponding 
alkylating partner (99),31 could only be synthesized in an optimized yield of 45% from 
1,2,3-tribromopropane (Scheme 3.2, Equation 2).32  Furthermore, the alkylation 
reaction was considerably low yielding, presumably due to the high rate of 
decomposition of allyl iodide 99.  These obstacles prompted an early divergence 
from the originally proposed synthetic route towards butenolide fragment 89. 
BrPPh3 OH
O
Br OAc
AcBr, cat Zn
0 °C, then
93%
PPh3, 100 °C, then
K2CO3, H2O, MeOH
93%
(1)
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Br
I
Br Br
Br
Br
BrNaOH, H2O,
45%
I2, (CH3)2O,
85%
108 99 (2)
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1,2,3-
tribromo-
propane  
Scheme 3.2 Preparation of Wittig salt 102 and allyl iodide 99. 
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Since the difficulty incurred was brought upon by the instability of a vinyl 
bromide moiety, having the necessary oxygenation already fixed into the alkylation 
substrate, as opposed to being introduced at a later step, should have eliminated 
these issues.  Accordingly, although no attempts at such an alkylation had any 
literature precedence, it was proposed that an allylic iodide bearing ester 
functionality at the 2-position would be able to undergo asymmetric alkylation.  The 
alkylation could possibly occur via an SN2 or SN2’ addition, either of which would 
lead to the desired alkylation product, and further transesterification with chiral 
butene 96 would even expedite the synthesis of the butenolide RCM precursor.   
The alkylation studies were initiated with ethyl 2-(iodomethyl)acrylate (109, 
Scheme 3.3).  Known condensation of triethylphosphonoacetate with formaldehyde 
provided ethyl-2-(hydroxymethyl)acrylate (110).33,34  Attempts to directly transform 
the alcohol to the corresponding iodide were unsuccessful, so a two-step sequence 
involving conversion to the allyl bromide followed by iodination via a Finkelstein 
reaction31 was pursued (Scheme 3.3).  Unfortunately, iodide 109 demonstrated no 
reactivity with the sodium enolate of glycolate 98, and decomposition under strongly 
basic conditions using lithium diisopropylamide (LDA) made this an unviable 
alkylation substrate (Scheme 3.4, Equation 3). 
Believing that the analogous t-butyl ester would be more robust in a basic 
environment, attempts to synthesize methacrylic iodide 113 from alcohol 110 were 
pursued (Scheme 3.3).  However, following quantitative protection of the free 
alcohol moiety, all attempts to transesterify ethyl ester 112 were unsuccessful.  After 
countless trials, it was discovered that a Morita-Baylis-Hillman reaction of t-
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butylacrylate with formaldehyde could provide the intermediate hydroxymethylated 
acrylate,35 which could be transformed into the iodomethyl species (113) in good 
yield following a standard two-step procedure. 
 
Scheme 3.3 Preparation of acrylate alkylation partners. 
Asymmetric glycolate alkylation with t-butyl-2-(iodomethyl)acrylate (113) 
proved to be much more successful than its ethyl equivalent, providing alkylation 
product 114 in good yield and with significantly complete diastereoselectivity 
(Scheme 3.4, Equation 4).  This appears to be the first example of an acrylic ester 
being employed as an electrophile in an asymmetric alkylation reaction. 
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Scheme 3.4 Glycolate alkylations employing (iodomethyl)acrylates. 
Further reduction of the chiral auxiliary gave the corresponding primary 
alcohol (115) in good yield (Scheme 3.5).  Nonetheless, subsequent attempts at 
hydrolysis of the t-butyl moiety were fruitless, and the approach employing 
carboxylate-containing alkylating agents was consequently abandoned. 
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2. hydrolysis
PO
OPMB
COOH
1. oxidation
2. olefination
3. hydrolysis
OPMB
COOH
116
117
( )3HO
 
Scheme 3.5 Attempted hydrolysis of t-butylacrylate alkylation substrate. 
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Next a route was explored wherein the carboxylate functionality would be 
masked as a protected alcohol.  Various protected alcohols (112), synthesized in 
previous investigations of acrylate hydrolysis (Scheme 3.3), were reduced to mono-
protected bis-allylic alcohols 118-120, which in one step, unlike their acrylate 
relatives, could be transformed into their corresponding allylic iodides 121-123 via a 
Finkelstein interconversion (Scheme 3.6).31 
 
Scheme 3.6 Synthesis of allylic iodides 121-123 as masked acrylates. 
The subsequent alkylation occurred in good yield and excellent 
diastereoselectivity, and since the best results were obtained when using TBS-
protected allyl alcohol 122 as the latent carboxylate, TBS-protected derivative 125 
was brought on through the remainder of the synthesis of the butenolide fragment 
(Scheme 3.7). 
Removal of the chiral auxiliary provided primary alcohol 127, which was 
oxidized and subjected to a Wittig olefination to affect the skeletal elongation.  Unlike 
previous routes, the olefination employed t-butyldiphenylsilyl (TBDPS)-protected 
Wittig salt 128, which not only increased the UV activity of the product, but further 
allowed for the elimination of an imminent protection step on the substrate.  Finally, 
selective deprotection of the allyl alcohol and ensuing two-step oxidation provided 
acrylic acid 131 in good yield over two steps. 
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Scheme 3.7 Synthesis of acrylic acid 131. 
2. Preparation of Alcohol 96 
It was envisioned that the ensuing coupling with (R)-3-buten-2-ol (96) would 
be accomplished via a Mitsunobu esterification.36  This was based on the strategy’s 
prior success in the synthesis of (+)-giganticin.21  The alcohol necessary for the 
ensuing coupling had been previously synthesized in four steps from (R)-isobutyl 
lactate.  However, it was found that with volatility of the alcohol (bp = 92 °C) 
impeded its successful isolation following the deprotection step (Scheme 3.8, 
Equation 5). 
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Scheme 3.8 Preparation of chiral alcohol 96. 
Moreover, the unnatural enantiomer of the lactate starting material was quite 
expensive, and thus, even if the route could be optimized, and a minimal amount of 
product isolated, the sequence would still be considered quite uneconomical.  While 
the preparation employing the inexpensive natural enantiomer (ent-96) would 
similarly be low yielding, the low cost of the starting L-ethyl lactate could make up for 
its low yielding synthesis.   However, even after reaction optimization, a useful 
amount of the desired alcohol could never be cleanly isolated.  Believing that the 
terminal deprotection step was causing the problems with the isolation, a two-step 
sequence starting from inexpensive, commercially available L-lactide was pursued.  
Unfortunately, reduction to the corresponding bis-lactol (134), followed by methylene 
Wittig olefination was only able to furnish alcohol ent-96 in 25% yield (Scheme 3.8, 
Equation 6).  Although complete conversion to the alcohol was achieved, it appears 
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that the product could not be efficiently removed from the triphenylphosphine oxide 
solid produced from the olefination reaction. 
3. Relay Ring-Closing Metathesis towards the Preparation of 
 Butenolide 89 
 
The failure met while isolating the necessary chiral butenol prompted us to 
reconsider the character of the chiral alcohol.  Mainly, it was predicted that 
increasing its mass would decrease the volatility, thus easing the problematic 
isolation of chiral butenols 96 and ent-96.  The issue remained of increasing the 
molecular weight while still maintaining the necessary functionality and reactivity of 
the terminal olefin for the ensuing RCM reaction.  A relay ring-closing metathesis 
(RRCM) strategy, recently demonstrated by Hoye and coworkers,37 appeared to be 
a technique that could control both of these issues (Figure 3.3).   
Hoye illustrated this strategy in the metathesis of 1,1-disubstituted dienes 
138, which are typically inert type IV olefins to metathesis employing Grubbs’ first 
generation catalyst (G1, 135).38,39  The lack of reactivity of 1,1-disubstituted olefins is 
attributed to the inability of the metal to insert into the hindered olefin and form the 
requisite metallocyclobutane intermediate.  Hoye believed that insertion could be 
forced to occur by extending one of the arms of the diene to form triene 141.  The 
type I terminal olefin would then undergo swift insertion of the metal to form carbene 
142, which would similarly undergo facile RCM, expelling 3-methylcyclopentene 
while resulting in the metallocarbene 139.  With the metal inserted into the typically 
non-reactive olefin, the resultant intramolecular ring-closing metathesis would be 
able to occur, forming typically inaccessible tetrasubstituted cyclopentenes 140. 
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Figure 3.3 Hoye’s relay ring-closing metathesis strategy. 
The RRCM strategy had been employed in the Crimmins laboratory in the 
synthesis of (-)-mucocin (143, Scheme 3.9).22  However, instead of exploiting the 
technique to enhance the reactivity of stubborn olefins, it was alternatively used as a 
way to differentiate between the three allylic olefins of equivalent reactivity.  Initially, 
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the RCM of triene 144 provided dihydrofuran 145 and dihydropyran 146 as products 
in a 1:1 ratio, resulting from non-selective insertion of the catalyst into any of the 
olefins (Scheme 3.9, Equation 7). 
 
Scheme 3.9 Relay ring-closing metathesis in the synthesis of (-)-mucocin (143). 
It was believed that selective insertion into the central olefin would result in 
sole formation of the desired dihydrofuran ring (Scheme 3.9).  The ensuing RCM 
would primarily result in dihydrofuran formation (filled arrows) over the highly 
energetically unfavorable cyclobutene formation (dashed arrows).  It was thus 
proposed that chain extension of the central olefin would provide the necessary 
discrimination between the three olefins, and a similar relay process as put forth by 
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Hoye would ensue.  In the event, exposure of tetraene 147 to Grubbs’ second 
generation catalyst (G2, 136) provided solely desired dihydrofuran 148, 
demonstrating the success of selective metal insertion into the least hindered bis-
allylic olefin (Scheme 3.9, Equation 8). 
Rather than employing the RRCM strategy to affect activated or selective 
insertion, the current synthesis would benefit from the introduction of added steric 
bulk to increase the molecular weight of the alcohol, while still providing the same 
ring-closed product in the ensuing RCM reaction.  The added carbon fragment would 
be sacrificed during the relay metathesis of the butenolide ring. 
The synthesis of bis-allylic alcohol 155 was thus pursued (Scheme 3.10).  
Protection of L-ethyl lactate as the t-butyldiphenylsilyl (TBDPS) etheriii provided ester 
149, which was reduced to the corresponding aldehyde.  Olefination employing 
ethyl(triphenylphosphoranylidine)acetate40 yielded α,β-unsaturated ester 151, which 
was then reduced to allylic alcohol 152.  Alkylation gave ether 153, which was 
deprotected under standard conditions to provide the desired bis-allylic alcohol (154) 
in 89% over two steps. 
Since the pursued alcohol originated from the inexpensive natural lactate 
derivative, the original esterification strategy, which would occur with inversion of 
stereochemistry at the α-stereocenter, was revisited.  Several test reactions of 
standard esterification procedures revealed that application of the Yamaguchi 
reagent41 at elevated temperatures would offer optimal yields for the esterification.  
                                                
iii A similar sequence wherein the TBS protecting group was employed provided products in 
significantly lower yield in each step. 
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In the event a related esterification proceeding through the pivaloyl anhydride was 
pursued, giving ester 155 in good yield (Scheme 3.10). 
 
Scheme 3.10 Preparation of relay ring-closing metathesis precursor 155. 
A litany of conditions were investigated in their ability to affect efficient RRCM 
to form the butenolide ring of the right-hand fragment (Table 3.1).  However, yields 
were unexpectedly disappointing, and most attempts provided abridged ring-opened 
fragment 156 (Figure 3.4).  Mechanistically, carbene insertion into the least 
hindered olefin of bis-allylic alcohol 155 should provide carbene 158.  Swift 
intramolecular RCM would then furnish carbene 160 with concomitant expulsion of 
dihydrofuran.42,43  This intermediate can then either undergo an intermolecular [2+2] 
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cycloaddition with styrene which, upon decomposition of metallocyclobutane species 
161, would provide the observed opened byproduct 156. 
 
Figure 3.4 Proposed mechanism for observed products of relay ring-closing 
metathesis. 
Conversely, an intramolecular [2+2] addition would result in 
metallobicyclobutane 162, which should lead to the desired ring-closed butenolide 
157.  Even though the intramolecular [2+2] cycloaddition should be favored 
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entropically over the intermolecular variant, no alteration of conditions including 
catalyst, concentration, pressure, and addition sequence improved the yield of ring-
closed butenolide 157, providing the desired product in an optimized yield of only 
44% (Table 3.1, Entries 1-13). 
Table 3.1 Optimization of conditions of relay ring-closing metathesis. 
Entry Cata Solventb Temp Time Conditions Yieldc 
1 136 CH2Cl2 reflux 1 h  24% 157 
2 136 CH2Cl2 reflux 12 h  37% 156 
3 136 CH2Cl2 23 ˚C 12 h  33% 157, 67% 156 
4 135 PhCH3 40 ˚C 12 h  44% 157, 56% 156 
5 137 CH2Cl2 reflux 12 h  --- 
6 135 PhCH3 reflux 12 h slow addn of 
ester to cat 
--- 
7 136 CH2Cl2 reflux 12 h slow addn of 
cat to ester 
23% 157 
8 136 CH2Cl2 reflux 1 h slow addn of 
ester to cat 
42% 157, 58% 156 
9 136 CH2Cl2 100 ˚C 15 min μw, 200W complete 
10 136 PhCH3 120 ˚C 48 h sealed tube incomplete 
11 136 CH2Cl2 100 ˚C 10 min μw, 110W incomplete 
12 136 CH2Cl2 100 ˚C 60 min μw, 200W incomplete 
13 136 (CH2)2Cl2 150 ˚C 60 min μw, 300W incomplete 
14 136 PhH 55 ˚C 30 min 0.1 eqv 1,4-
benzoquinone 
--- 
15 136 PhH reflux 12 h sparging with Ar 70% 157 
a10-15 mol % of catalyst were employed. 
bAll reactions were performed at 2 µM except entry 5, which was performed at 50 µM. 
cEntries 10-14 all provided 157 as the major product but in very poor yields. 
 
 
One prediction was that if formation of metallocyclobutane 162 was the rate-
limiting step, not only could formation of opened product 156 interfere, but also 
decomposition of the active catalyst into a harmful ruthenium hydride species could 
be deactivating the catalyst faster than the desired RCM.44  To probe this possibility, 
a catalytic amount of 1,4-benzoquinone, an additive recognized in its ability to 
prevent the formation of such a debilitating species, was introduced into the reaction 
(Table 3.1, Entry 14).  However, the additive, as well as other benzoquinone 
derivatives,44 provided only decomposition products, and the investigation turned 
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instead towards increasing the rate of the intramolecular metallocyclobutane 
formation. 
During our investigations into the RRCM chemistry, Reiser and coworkers 
published a strategy that was able to overcome the sluggish RCM of particularly less 
reactive dienes.  In their efforts toward the total syntheses of (+)-arglabin (163) and 
its related guaianolide natural product ixerin Y (164), they envisioned the 
tetrasubstituted olefin of ixerin Y to arise from the RCM of diene 165 (Figure 3.5).45 
 
Figure 3.5 Reiser’s ring-closing metathesis of 1,1-disubstituted olefins. 
Despite the great potential of closing cyclic natural products with 
tetrasubstituted double bonds via ring-closing metathesis, it is well-known that the 
metathesis of 1,1-disubstituted olefins has exhibited immense difficulty.39  
Unsurprisingly, RCM under typical thermal conditions could only provide the desired 
tetrasubstituted cyclohexene 166 in 35% yield.  However, the researchers were able 
to surmount this issue employing a combination of microwave heating as well as 
inert sparging of nitrogen gas into the reaction system, increasing the yield to 98%.  
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The bubbling of a dense, inert gas throughout the system should immediately 
remove any ethylene gas, evolved from the RCM (Figure 3.4, Equation 9), from the 
reaction solvent. In turn, the rate of the RCM should be increased by forcing the 
equilibrium state towards the formation of ethylene, and thus the ring-closed product. 
Similar conditions were applied to bis-allylic alcohol 155.  While microwave 
conditions did not provide improved yields over sealed tube conditions (Table 3.1, 
Entries 9-13), sparging inert argon through the solvent increased the yield of the 
RRCM to 70%, without the trace of any of the straight-chain byproduct (156).  
Furthermore, sparging in the current system should drive off the evolved 
dihydrofuran in addition to ethylene (Figure 3.4, Equation 9), further increasing the 
rate of the cascade RRCM sequence. 
Ultimately, deprotection of the eastern fragment (157) was affected by 
buffered triethylamine hydrofluoride, as other basic and acidic fluoride sources led to 
decomposition of the butenolide moiety.  Subsequent oxidation via Swern’s 
protocol28 provided aldehyde 89 in good yield, primed for the impending coupling. 
 
Scheme 3.11 Completion of butenolide fragment 89. 
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4. Glycolate Aldol Approach towards Dihydropyran 88 
The synthesis of the western fragment would rely upon a key glycolate-RCM 
strategy to install the stereodefined THP ring (Scheme 3.12).  A glycolate aldol 
reaction17 between benzylglycolyloxazolidinone 93 and tridecanal (94), prepared via 
oxidation of commercially available tridecanol with pyridinium chlorochromate (PCC), 
provided aldol adduct 167 in good yield and excellent diastereoselectivity.  This 
reaction ensured the early setting of the stereocenters at C19 and C20.  The 
secondary alcohol was then protected as its triethylsilyl (TES) ether, and the 
oxazolidinone chiral auxiliary was reductively removed under standard conditions.  
Oxidation of the primary alcohol (169) followed by Wittig methylenation provided 
protected diol 170, which was selectively deprotected under fluorine conditions to 
provide the secondary alcohol (171).  Subsequent alkylation of the free alcohol with 
bromoacetic acid gave glycolic acid 172, and further transformation into 
glycolylimide 91 was accomplished via nucleophilic addition of oxazolidinone 173 to 
the intermediate pivaloyl anhydride (Scheme 3.12).  Unfortunately, the ensuing aldol 
reaction, which would establish the stereocenters at C15 and C16, was problematic, 
providing only a minimal amount of product along with mainly recovered starting 
material.  Studies on the behavior of glycolate 91 under soft enolization conditions 
revealed that both the initial deprotonation and subsequent attack of an aldehydic 
partner are extremely sluggish at -78 °C, and it was apparent that the temperature 
needed to be raised in order to affect complete enolization and reaction.  However, it 
was necessary to acertain a temperature that created a balance between reactivity  
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Scheme 3.12 Glycolate aldol strategy towards the preparation of the tetrahy-
dropyran ring. 
reaction.  Traditionally, titanium-mediated glycolate aldols are subjected to soft 
enolization at -78 °C, and complex glycolates are often warmed to -45 °C for two 
hours in order to promote complete enolization of the glycolylimide.22  While this 
technique appeared to propel the ensuing coupling with aldehyde 92 forward, the 
glycolate was still never completely consumed, even with the addition of up to five-
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fold excess of the aldehyde.  This suggested that enolization of glycolylimide 91 was 
still incomplete.  In order to optimize enolization conditions, rate studies on the 
decomposition of its corresponding enolate were probed.  After treatment with 
titanium tetrachloride and Hünig’s base at -78 °C, the glycolate was slowly warmed 
over 12 hours to -10 °C.  While some decomposition of the enolate was immediately 
noticeable upon enolization, severe decomposition was not detected until warming 
to -30 °C.  The optimized reaction conditions required enolization at -45 °C over two 
hours, and after the addition of aldehyde 92 at -78 °C (prepared via successive 
alkyne protection and oxidation of commercially available 4-pentynol) warming to -45 
°C overnight afforded aldol adduct 174 in very high diastereoselectivity, although the 
reaction still never proceeded with complete consumption of the starting glycolate.   
 
Figure 3.6 Crystal structure of aldol adduct 174.iv 
                                                
iv Courtesy of Dr. Peter White 
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X-ray crystallography of the crystalline product confirmed the configuration of 
the two stereocenters formed in the aldol reaction (Figure 3.6).iv 
In the protection of the resulting secondary alcohol, it was desired to employ a 
protecting group that would be orthogonal to the triisopropylsilyl (TIPS) protecting 
group already installed in the molecule.  Although the small size of the 
methoxymethyl (MOM) group made it an attractive candidate for protection, multiple 
attempts at protecting the hindered alcohol were met with difficulty.  
An effort towards acylation was further pursued, yet acyl transfer in the 
ensuing reduction step prevented this strategy from becoming an amenable route.  
Instead, believing that the carbon-silicon bond of the alkyne would selectively cleave 
prior to a stronger oxygen-silicon bond, alcohol 174 was protected as the triethylsilyl 
(TES) ether.  Reductive removal of the chiral auxiliary provided primary alcohol 176, 
which under the same two-step protocol as previously followed (Scheme 3.12), was 
transformed into diene 177.  The ensuing RCM occurred quantitatively to yield 
dihydropyran 178 (Scheme 3.13). 
Unfortunately, all attempts at selective deprotection of the alkyne over the 
alcohol (179) were unsuccessful, affording only the unprotected secondary alcohol 
(180) or the fully deprotected product (181, Table 3.2). 
Since acetylenes protected as smaller trimethylsilylacetylenes have been 
observed to participate in RCM reactions, the size of the protecting group could not 
be compromised.  An alternative two-step non-selective deprotection/protection 
strategy was thus employed to provide acetylenes 182 and 183 (Table 3.3), suitable 
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for the ensuing addition to aldehyde 89 to unite the pyrancin backbone, while 
concurrently establishing the stereocenter at C10. 
 
Scheme 3.13 Completion of the tetrahydropyran fragment. 
  Table 3.2 Attempts at selective deprotection of TIPS-acetylene 178. 
Conditions Results 
NaOMe, MeOH, RT to reflux 180 only 
K2CO3, MeOH, RT to reflux 180 only 
I M NaOH, THF/MeOH 180 only 
AgNO3, 2,6-lutidine incomplete rxn, 181 only detected pdt 
TBAF, THF 181 only, 93% 
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5. Asymmetric Alkynylzinc Addition 
Carreira’s asymmetric alkynylzinc methodology46-48 has been employed in the 
total synthesis of a number of annonaceous acetogenins, particularly towards the 
installation of remote stereocenters common to the backbone of these natural 
products.  The strategy relies on the soft deprotonation of terminal acetylenes to 
form the corresponding alkynylzinc species.  Upon addition of a chiral amino alcohol 
as a ligand and an aldehyde, a chiral bis-zinc chelate49,50 (184) originally proposed 
by Noyori51-54 is possibly responsible for the high enantiomeric excess observed in 
the propargyl alcohol products (Scheme 3.14). 
 
Scheme 3.14 Conditions and possible model for selectivity in Carreira asymmetric 
alkynylzinc addition methodology. 
Unfortunately, exhaustive attempts towards converging the eastern (89) and 
western (182 or 183) fragments were fruitless (Table 3.3).  The advanced coupling 
partners (1.0-1.5 equivalents each) were initially reacted under conditions that have 
previously been successful in our laboratory,55 employing 2-3 equivalents of zinc 
triflate as the source of the metal, 2-3 equivalents of (+)-N-methylephedrine (NME, 
185) as the chiral ligand, and excess triethylamine (2-5 equivalents) as the base 
(Table 3.3, Entries 1-2).  However, no reaction was observed under any conditions. 
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Closer scrutiny of the literature revealed no examples of the successful 
addition of complex acetylides to aldehydes.  Furthermore, very few instances of 
successful Carreira-type acetylenic additions of alcohol-containing alkynes have 
been recorded.  In the few successful examples, the alkynes are limited to activated, 
electron rich propargyl alcohols,56 or conversely, the aldehydes have been 
constrained to non-enolizable, activated aldehydes and α-ketoesters.57,58  The lack 
of significant precedent made it necessary to assess the viability of the Carreira 
coupling of a non-propargylic alcohol.  A model system consisting of homopropargyl 
alcohol and simple protected homopropargylic alcohols (189, 190), to mimic the 
alcohol-containing alkyne fragment, and tridecanal (94), to mimic the long-chain 
aldehyde of the butenolide fragment, was pursued (Table 3.3).  However, standard 
Carreira coupling conditions were insufficient to elicit any reaction between 
tridecanal and any of these alkynes.  Both (+)-NME (185) and (-)-NME (186) were 
evaluated, unfortunately leading to no reaction between the two partners. 
A survey of the literature further revealed that not only were the acetylenic 
substrates that had demonstrated successful Carreira additions quite simple, but 
also they were used in extreme excess, typically 5-10 equivalents.  Because both 
the alkyne and aldehyde fragments for the desired backbone coupling were late-
stage compounds, this would not be a viable option for our route.  Recently, Carreira 
overcame this economical issue in the synthesis of (R)-strongylodiols A and B, by 
alternatively increasing the equivalents of zinc triflate and the chiral ligand.59  The 
same conditions were thus applied to the model system.  Four equivalents of zinc 
triflate and three equivalents of (+)-NME were thus added to the system, and 
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sonication was employed to promote the dissolution of the excess solids at room 
temperature.  Although these conditions did increase the yield of the reaction, the 
25% isolated yield was still quite unsatisfactory (Table 3.3, Entries 10,15).  
Sonication, when paired with slow addition of the aldehyde to the zinc acetylide 
species, was able to further increase the reaction output,59 but the 45% yield still left 
room for improvement (Table 3.3, Entry 11). 
Ligand 187,60 prepared from (1S,2S)-(+)-1-phenyl-2-amino-1,3-propanediol 
via two protection steps,61 was also evaluated (Table 3.3, Entries 5, 9).  
Unfortunately, the ephedrine-based amino alcohol, proposed by Jiang to offer high 
yields and enantioselectivities57,58,62-64 due to the enhanced solubility of the 
alkynylzinc-ligand intermediate,60 further afforded unsatisfactory results.    
Alternatively, exchanging the zinc source for dimethylzinc and the ligand for (R)-
BINOL (188, Table 3.3, Entries 6, 13, 14) did not improve the results.65-69 
The viable options for the Carreira-type addition had been exhausted, and 
disappointingly, the yield employing the model system could only be optimized to 
45%.  Grudgingly, the Carreira-type addition of complex zinc-acetylide 184 to late-
stage aldehyde 89 was deemed an impractical route for the construction of the 
pyranicin backbone. 
Instead of abandoning the current route completely, the most economical 
option would be a non-selective acetylide addition with the complex acetylene and 
aldehyde at our disposal.  The resultant racemic propargyl alcohol 191 would be
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oxidized, and stereoselective reduction would provide the desired chiral alcohol 192 
(Scheme 3.15). 
 
Scheme 3.15 Proposed racemic addition/oxidation/asymmetric reduction strategy. 
Although this would increase the length of the synthetic route by two steps, 
the ability to fuse the backbone and establish the stereocenter and C10 from 
fragments that had already been synthesized was quite attractive.  A similar strategy 
was adopted by the Baldwin group in their total synthesis of (R)-strongydiols 
(Scheme 3.16).70  After numerous attempts to affect the Carreira-type coupling of 
trimethysilylacetylene with aldehyde 193 provided no desired coupling product 194, 
an alternative route was considered, wherein the corresponding activated lithium 
acetylide was added in a racemic manner.  Alcohol 195 was oxidized, and 
subsequent asymmetric transfer hydrogenation using Noyori’s catalyst 71-74 was then 
able to provide the desired alcohol 194, which was advanced to (R)-strongylodiol B. 
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Scheme 3.16 Baldwin’s approach to (R)-strongydiols. 
Unfortunately, initial attempts to add the lithiated acetylide of 183 to aldehyde 
89 in an analogous manner were disappointing, providing racemic alcohol 191 in 
only 20% yield (Scheme 3.15).  Instead of optimizing the conditions of the alkyne 
addition reaction, the oxidation/reduction strategy was reevaluated.  Transfer 
hydrogenation under Noyori’s conditions, while predicted to provide high facial 
selectivity, would likely reduce the electron rich butenolide in the process.  While this 
could be overcome with protection strategies, the economy and efficiency of the 
synthetic route would be further diminished as more steps would be added to the 
synthetic route.  Alternatively, asymmetric reductions of non-conjugated ketones are 
typically affected by hydrogenation employing the Corey-Bakshi-Shibata (CBS) 
catalyst.75,76  It was predicted, however, that the catalyst would be unable to 
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influence facial differentiation due to the steric similarities between the alkyl groups 
on either side of the ketone. 
After arduous trials failed to efficiently forge the pyranicin backbone while 
introducing the stereocenter at C10 late into the total synthesis, we pursued a 
revised route that would incorporate the stereocenter from the beginning.   
C. Second Generation Approach towards Pyranicin 
A route was designed so that late-stage intermediates that had been 
previously synthesized for the initial total synthesis could still be employed (Figure 
3.8).  The pyranicin carbon backbone was envisioned to arise from a tandem ring-
closing metathesis/cross metathesis reaction that would close the tetrahydropyran 
ring while concurrently joining the left and right-hand fragments.  Triene 199 would 
be synthesized in a manner similar to THP 178, intercepting the previous 
retrosynthesis at glycolyloxazolidinone 91 with an aldol reaction with aldehyde 202.  
To avoid any late-stage problems concerning stereocenter installation, the aldehyde 
would arise from the bidirectional elaboration of (R)-benzyl glycidyl ether (203),v 
which already possesses the necessary alcohol stereocenter at C10.  The 
butenolide fragment (200 or 201) would also be prepared by a protocol analogous to 
that employed in the first-generation approach to pyrancin, arising from alkylation 
product 127. 
                                                
v Donated by Daiso, Inc. 
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Figure 3.8 Second generation retrosynthesis of pyranicin. 
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1. Preparation of Aldehyde 202 
Early efforts focused on the synthesis of aldehyde 202.  The original synthetic 
plan was to initially install the terminal olefin (Scheme 3.17).  Thus, addition of the 
cuprate derived from but-3-enylmagnesium bromide to (R)-benzyl glycidyl ether 
(203) provided monoprotected diol 207.  In order to elaborate the other side of the 
target molecule, it was necessary to reform an epoxide.  The benzyl group was 
subsequently removed, and the primary alcohol selectively tosylated to provide 
alcohol 209. 
Unfortunately, all attempts to recover epoxide 210 after treatment with base 
(sodium hydride and 18-crown-6, 10 M sodium hydroxide, and potassium carbonate 
in MeOH) were unable to provide a sufficient amount of the desired product, possibly 
due to loss of the volatile low molecular weight molecule during reaction workup. 
 
Scheme 3.17 Initial synthetic attempt towards aldehyde 202. 
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To alleviate this issue, it was resolved that the synthesis of aldehyde 202 
should be approached from the opposite side.  The introduction of a protected 
alcohol, that would later be unprotected and oxidized to the aldehyde, would provide 
added molecular weight that would potentially facilitate isolation of the intermediate 
epoxide.  Thus, 6-heptenol was protected as the PMB ether (Scheme 3.18).  
Asymmetric dihydroxylation77 of the olefin provided the corresponding diol (211), 
which was further transformed into primary tosylate 212.  As predicted, the added 
bulk allowed for facile isolation of epoxide 213 after base-promoted displacement.  
However, Mosher ester analysis78 of tosylate 212 revealed that the asymmetric 
dihydroxylation provided the diol in an a mere 1.5:1 ratio of enantiomers. 
 
Scheme 3.18 Asymmetric dihydroxylation approach towards aldehyde 202.  
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In order to obtain epoxide 213 in high yield and stereochemical purity, 
racemic epoxide rac-213, prepared in two steps from 6-heptenol, was instead 
subjected to a hydrolytic kinetic resolution (HKR) employing cobalt(salen) complex 
(S,S)-216,79,80 which has been demonstrated to deliver highly enantioenriched 
terminal epoxides (Scheme 3.19).  Consequently, (S)-epoxide 213 underwent 
copper-promoted addition of but-3-enylmagnesium bromide to provide the 
corresponding alcohol (214).  Ensuing silyl protection, selective deprotection of the 
PMB ether, and oxidation81 provided the target aldehyde (202) in good yield over 
three steps. 
 
Scheme 3.19 Hydrolytic kinetic resolution approach towards aldehyde 202. 
Although the designed route had made the desired aldehyde easily 
accessible, the high cost of 6-heptenol made a kinetic resolution inefficient and 
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uneconomical.  Another less costly route towards epoxide 213 was thus pursued 
(Scheme 3.20).  Lewis acid promoted addition of lithiated homopropargyl alcohol 
217 (prepared in quantitative yield from 3-butynol under standard protection 
conditions) to (S)-benzyl glycidyl ether (ent-203) provided heptyne 218. 
 
Scheme 3.20 Optimized synthesis of aldehyde 202. 
Reduction of the alkyne and selective removal of the benzyl group was most 
effective employing Raney nickel, giving diol 211.  Although selective tosylation of 
this diol had been previously accomplished using pyridine as the solvent, the results 
were inconsistent, and a significant amount of the bis-tosylate byproduct was often 
isolated.  It was proposed that this lack of discrimination between the primary and 
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secondary alcohols was due to the similarities in their steric environments, and that 
a bulkier agent would be able to afford the mono-protected product (Scheme 3.20).  
Accordingly, reaction of diol 211 with 2,4,6-triisopropylbenzenesulfonylchloride 
(TrisCl) under standard sulfonylation conditions consistently gave the mono-
trisylated product (219) in good yield, which could be treated with base to afford 
epoxide 213.  The revised economical approach to intermediate epoxide 213 thus 
allowed access to desired aldehyde 202, following the three-step sequence 
previously described, in good yield and high enantiopurity. 
2. Glycolate Aldol Strategy towards the Preparation of 
 Triene 199 
The synthesis of triene 199 was proposed to follow a five-step sequence from 
glycolate 91 analogous to that previously described for the first generation approach 
(Scheme 3.21).  Unsurprisingly, the problematic glycolate aldol of the original 
synthetic plan similarly plagued the newly designed total synthesis.  The stubborn 
enolization was overcome by enolizing glycolylimide 91 at -45 °C for 12 hours, 
cooling back down to -78 °C for the NMP and subsequent aldehyde addition, and 
after reaction for six hours at that same temperature, stirring at -45 °C for another 12 
hours to coax the reaction forward.  While complete condensation was still never 
achieved, these optimized conditions were able to provide the desired alcohol (220) 
as a crystalline solid in 74% yield (based on recovered starting material).  The 
familiar sequence of silyl protection, chiral auxiliary removal, oxidation and 
methylenation was followed as before, giving triene 199 in good yield over four 
steps. 
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Scheme 3.21 Glycolate aldol approach towards triene 199. 
3. Preparation of Butenolide Substrates 200 and 201 
Upon first glance it appeared that the approach to condensed butenolide 
fragments 200 and 201 would, like triene 199, proceed through a sequence identical 
to that of its first generation congener (Equation 10).  The only difference would be 
that a simple methylene Wittig would replace the original Wittig olefination with 
complex phosphonium salt 128. 
HO
OPMB
OTBS
OPMB
OTBS
R
222 R = H
223 R = CH3
127
(10)
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However, early concerns about possible competition between eight-
membered oxocine ring closure and the desired five-membered ring closure in the 
ensuing RRCM reaction lead us in the direction of employing protected alcohol 224.  
The protected alcohol would be inactive during the RCM, yet could be easily 
transformed into the desired olefin immediately following the closure of the 
butenolide ring (Scheme 3.22). 
HO
OPMB
OTBS
127
1. TBDPSCl, imidazole
CH2Cl2, 99%
2. PPTS, EtOH, 60 °C
89%
TBDPSO
OPMB
OH
1. DMP
NaHCO3, CH2Cl2
2. NaH2PO4 H2O,
2-methyl-2-butene,
NaClO2, t-BuOH, H2O
92% over 2 steps225
TBDPSO
OPMB
COOH
TBDPSO
OPMB
OO
O
136, PhCH3
reflux, sparging
78%
TBDPSO
PMBO
O
O
204 224
HF-NEt3, THF
3 days
76%
HO
PMBO
O
O
1. oxidation
2. Wittig
226 227
OPMB
O
O
R
200 R = H
201 R = CH3
TEA, PivCl
THF, -78 °C to -20 °C;
then 154, DMAP
PhCH3, 60 °C, 3 h
50%
 
Scheme 3.22 Protected ether approach to butenolides 200 and 201. 
Alcohol 127 was accordingly protected as the TBDPS ether, and butenolide 
fragment 226 was prepared following the same sequence performed on its parallel 
elongated substrate (155, Scheme 3.10). Subsequent fluoride-promoted 
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deprotection gave the primary alcohol, which was then oxidized under various 
conditions.  However, neither methylene nor ethylene Wittig olefination was able to 
affect the necessary conversion to the olefin.vi  These results suggested that the 
presence of the butenolide ring was somehow inhibiting late stage olefination, and 
that the olefin must be installed prior to the cyclization of the butenolide (Scheme 
3.22). 
It was desirable to synthesize ethylene-containing substrate 231 in parallel 
with its methylene counterpart, because if the sterically unencumbered terminal 
methylene unit were to inopportunely participate in the ensuing RRCM, a more 
hindered ethylene moiety would retard metal insertion, and thus participation of the 
undesired olefin, in the metathesis reaction.  Adhering to the synthetic strategy 
previously outlined (Scheme 3.7), alcohol 127 was oxidized and subjected to both 
methylene and ethylene Wittig olefinations, providing olefins 222 and 223 in 
excellent yield over two steps. 
Standard fluoride-mediated deprotection provided allylic alcohols 228 and 
229, which underwent two-step oxidations to the corresponding acrylic acids (205 
and 206).  Esterification via the pivaloyl anhydride intermediate yielded RRCM 
precursors 230 and 231.  Fortunately, the ensuing RRCM of both tetraenes, 
catalyzed by G2 (136), proceeded to give selective cyclization to the five-membered 
butenolides 200 and 201, exclusively.  Both of these butenolide fragments would be 
                                                
vi A similar approach had been attempted in the first generation synthesis, and the final olefination 
with Wittig salt 128 was met with difficulties as well. 
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examined in their ability to affect the subsequent cross metathesis towards building 
the pyranicin backbone. 
 
Scheme 3.23 Synthesis of methylene- and ethylene-substituted butenolides 200 and 
201. 
4. Investigations into the Tandem RCM/CM Strategy 
The economy and efficiency of one-pot multi-component reactions in organic 
synthesis made the proposed tandem ring-closing metathesis/cross metathesis82 an 
attractive strategy for the construction of the pyranicin skeleton (Figure 3.9).  Ideally, 
with all of the components of the reaction present at the reaction outset, ring-closing 
metathesis of triene 199 would occur swiftly.  The ensuing cross metathesis with 
butenolide 200 or 201 would be secondary, occurring much slower due to its 
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bimolecular nature.  Because of the inherently slower rate of cross metathesis, the 
butenolide would selectively react with the remote olefin of intermediate 232, 
providing crossed product 198 (Figure 3.9). 
 
Figure 3.9 Proposed mechanism of RCM-CM strategy. 
Initially, ambitious attempts at performing the two transformations together 
were unsuccessful, providing no discernable product but significant recovered 
starting material (Table 3.4, Entries 1-3).  Since successful product formation would 
depend upon complete formation of dihydropyran 232, conditions for ring closure 
were probed, in order to rule out incomplete RCM as the culprit for the observed 
inactivity (Table 3.5).  Reaction concentration, temperature, and time all appeared to 
influence the ability of triene 199 to form the necessary ring-closed intermediate 
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(232).  In fact, it was observed that elongated exposure of triene 199 to G2 (136) in 
benzene at 80 °C provided ring-closed dimer 233 (Figure 3.10), while shorter 
reaction times were able to give ring-closed monomer products. 
 
Figure 3.10 Formation of ring-closed dimer 233. 
Thus, with the metathesis conditions previously attempted (Table 3.4, Entries 
1-3), the triene was most likely transforming into the dimer in situ.  Although pre-
dimerization is a technique often exploited in the cross-metathesis of type I olefins,22 
it was certainly a possibility that dimerization to bulky bis-dihydropyran 233 could be 
shutting down the reactivity of the left-hand fragment completely, thereby accounting 
for the lack of cross metathesis products.  In fact, cross metathesis of monomer 232 
with butenolide 200 with G2 (136) at 60 °C, a temperature that would not likely 
instigate dimerization of the monomer, was able to give the coupled product 198 in 
22% yield (Table 3.4, Entry 6).  This feeble reaction yield represented a significant 
step towards understanding the behavior of the RCM/CM of the current system. 
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The above results suggested that dimerization of monomer 232 may have 
inhibited the western fragment’s capability to undergo cross metathesis.  
Unfortunately, even if monomer 232 was to be used as a coupling partner, the 
extremely sluggish nature of the cross metathesis with butenolide 200 would 
imminently facilitate cross metathesis/ dimerization of the monomer prior to cross 
metathesis with the desired substrate (Figure 3.9), particularly at elevated 
temperatures that would be used to push the cross metathesis forward.  This 
conundrum directed the research towards optimization of the cross metathesis 
between ring-closed dimer 233, uncontrollably formed under the metathesis 
conditions, and butenolide 200. 
A change in catalyst to Hoveyda-Grubbs second generation catalyst83 137 
(HG2) was able to push the reaction towards the desired product, however products 
were accompanied by a significant amount of decomposition of the metathesis 
partners under both thermal and microwave conditions.  The products were 
resultantly contaminated with a variety of inseparable byproducts (Table 3.4, 
Entries 7-10). 
Different solvent systems for the tandem reaction were investigated.  
Although studies on the ring closure of triene 199 revealed incomplete formation of 
dihydropyran 232 after seven hours in refluxing methylene chloride (Table 3.5, 
Entry 4), it was surmised that a longer reaction period would be able to push the 
ring formation forward, as well as the ensuing cross metathesis.  However, low 
concentrations in methylene chloride paired with longer reaction times did not result 
in any product formation.  At the other end of the spectrum, higher concentrations in  
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Table 3.4 Results of selected RCM-CM trials. 
Entry X(eqv) Y(eqv) Cata Conditions Resultsb 
1 199(1) 200(1) 136 0.1 M PhCH3, 80 °C, 12 h -- 
2 199(1) 200(1) 136 0.1 M PhCH3, 80 °C, slow addn of 
200 over 10 h -- 
3 199(1) 200(1) 136 0.1 M PhCH3, 80 °C, slow addn of 
199 over 10 h -- 
4 199(1) 200(1) 136 0.1 M PhCH3, 80 °C, 199, 136, 3 h; 
then slow addn of  200 + 136 over 10 
h -- 
5 232(1) 200(1) 136 0.1 M CH2Cl2, reflux, 24 h -- 
6 232(1) 200(1) 136 0.1 M PhH, 60 °C, 48 h 22%, 100% brsm 
7 199(1) 200(3) 137 0.3 M PhCH3, 60 °C, 12 h; then 80 °C 
12 h 15% (unclean) 
8 199(1) 200(3) 137 0.3 M PhCH3, 80 °C, 12 h 30-40% (unclean)
9 199(1) 200(3) 137 0.3 M PhCH3, µw, 100 °C, 1 h 50% (unclean) 
10 199(3) 200(1) 137 0.05 M CH2Cl2, µw, 60 °C, 1 h 30% (unclean) 
11 199(1) 200(1) 136 0.08 M CH2Cl2, 45 °C, 24 h -- 
12 199(3) 200(1) 136 0.05 M CH2Cl2, µw, 50 °C, 1 h -- 
13 199(1) 200(3) 136 0.02 M CH2Cl2, 45 °C, 12 h -- 
14 199(1) 200(1) 136 0.5 M CH2Cl2, 45 °C, 24 h 15% byproduct 
15 199 200 136 various, benzoquinone additive -- 
16 199 200 136 various, 2,5-dichlorobenzoquinone 
additive -- 
17 199(1) 200(1) 136 0.1 M CH2Cl2, 45 °C, 199, 136, 7 h; 
then redissolve in 0.1 M PhH, add 
200 + 136, 60 °C, 12 h 20%, 38% brsm 
18 199(1) 200(1) 136 0.01 M PhH, 80 °C, 199, 136, 3 h; 
then sparge at 45 °C to 0.1 M PhH, 
add 200 + 136, 45 °C, 20 h 18%, 100% brsm 
19 199(1) 200(1) 136 0.01 M PhH, 80 °C, 199, 136, 3 h; 
then sparge at 45 °C to 0.1 M PhH, 
add 200 + 136, 45 °C, 4 d 18%, 100% brsm 
20 199(1) 200(1)  0.01 M PhH, 80 °C, 199, 136, 3 h; 
then sparge at 45 °C to 0.1 M PhH, 
add 200 + 137, 45 °C, 24 h 13%, 100% brsm 
21 233(1) 200(1) 136 0.1 M CH2Cl2, rt 12 h; then 45 °C, 
12 h 16%, 60% brsm 
22 233(1) 200(1) 136 0.1 M CH2Cl2, 45 °C, 20 h 30%, 100% brsm 
23 233(1) 200(1) 136 0.1 M PhH, 80 °C, 3 h 15%, 100% brsm 
24 233(1) 200(2) 136 0.1 M CH2Cl2, 45 °C, 20 h -- 
25 233(1) 200(2) 136 0.1 M PhH, 80 °C, 3 h -- 
26 233(1) 200(3) 136 0.1 M CH2Cl2, 45 °C, 233, 136; slow 
addn of  200 over 4 h -- 
27 233(1) 200(3) 136 0.1 M PhH, 80 °C, 233, 136; slow 
addn of  200 over 4 h -- 
28 233(1) 200(2) 136 0.01 M PhH, µw, 100 °C, 1 h dimerization of 200
aAll reactions equipped with a catalyst loading of 10-15 mol %. 
bBRSM is based on recovered butenolide. 
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methylene chloride provided a byproduct that appeared by 1H NMR analysis to have 
incorporated both the triene and butenolide fragments, but not in the desired fashion 
(Table 3.4, Entries 11-14).  This suggested that butenolide 200 underwent cross 
metathesis with triene 199 prior to its ring-closure and/or dimerization, accounting for 
the formation of various olefinic byproducts. 
Table 3.5 RCM and dimerization studies of triene 199. 
Entrya Solvent Temp Time Results 
1 0.1 M PhH 80 °C 20 min 100% yield, 10:1 232:199 
2 0.1 M PhH 80 °C 40 min 100% yield, 1:1 232:233 
3 0.1 M PhH 80 °C 3 h 100% yield 233 
4 0.1 M CH2Cl2 45 °C 7 h mixture of 199,232,233 
5 0.01 M PhH 80 °C 6 h minimal ring closure of 199 
aAll triene dimerization studies were performed with 10 mol % of G2. 
Benzoquinone additives44 were further added to investigate their effect on the 
current tandem reaction (Table 3.4, Entries 15, 16).  Unfortunately, the addition of 
these auxiliary compounds, while minimizing degradation of the starting materials, 
did not promote any product formation. 
Since the one-pot tandem reaction pathway was providing no positive results, 
the approach was abandoned in favor of a stepwise sequence.   While less efficient 
than its tandem counterpart, such a modular approach would allow for the 
opportunity to finely tune the conditions towards each reaction, as opposed to 
compromising conditions of one reaction towards increasing the output of the other.  
Accordingly, RCM/dimerization of triene 199 was performed at various temperatures.   
After a solvent swap to benzene, or solvent reduction via sparging, butenolide 200 
and fresh G2 (136) were added.  Unfortunately, the yield of the cross metathesis 
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products was still extremely low, and neither increasing the reaction time nor 
changing the catalyst identity enhanced the product yield (Table 3.4, Entries 17-20). 
Decomposed catalyst has been observed to have a detrimental effect on 
ensuing reactions,84,85 even in the presence of fresh catalyst.  It was thus predicted 
that if the ring-closing metathesis/dimerization of triene 199 were performed alone, 
and the intermediate isolated, the clean dimer intermediate 233 could undergo 
cross-metathesis with butenolide 199 with the introduction of new catalyst.  Triene 
199 was consequently dimerized at 80 °C in dilute benzene (0.01 M) for three hours, 
and isolated in pure form via flash column chromatography.  Subsequent dilution in 
solvent and reaction with butenolide 199 and G2 at 45 °C was able to afford the 
desired cross metathesis substrate albeit with a maximum of 30% yield (Table 3.4, 
Entries 21-23). 
Interestingly, when two or three equivalents of butenolide 200, with respect to 
dimer 233, were employed, these same conditions failed to afford any productive 
product formation (Table 3.4, Entries 24-27).  Rather, at high temperatures, 
dimerization of butenolide 199 was observed (Table 3.4, Entry 28).  The 
stubbornness of the protected allylic olefin to dimerize at any temperature below  
100 °C prompted investigations into the general activity of the butenolide fragment 
(200).  Dimerization studies performed prior to the RCM/CM trials revealed, as 
expected, that the type II olefins of butenolides 200 and 201 would not dimerize 
(Table 3.6, Entries 1, 2).  It was originally believed that this difference in reactivity 
between the less reactive butenolide olefins and activated triene 199 could be 
exploited to our advantage in the selective cross metathesis reaction.  Unfortunately, 
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judging by the poor yields of cross metathesis products, it is plausible that the bulky 
PMB protecting group, while preventing the terminal olefin from dimerizing, may also 
be hindering the olefin from reacting with any substrate at all. 
Table 3.6 Cross- and Homodimerization studies of butenolide fragments. 
Entry Butenolide Partner Solvent Temp Time Results 
1 200  PhH 80 °C 24 h no dimerization 
2 201  PhH 80 °C 24 h no dimerization 
3 234  PhH 40, 80 °C 24 h no dimerization 
4 235  PhH 40, 80 °C 24 h no dimerization 
5 200 236 CH2Cl2 45 °C  12 h minimal coupling 
6 234 236 CH2Cl2 45 °C 12 h mostly 238 
7 235 236 CH2Cl2 45 °C 12 h 1:1 235:239 
 
To further examine this possibility, two electronically and sterically divergent 
butenolides were synthesized.  The PMB protecting group was removed under 
standard conditions to unveil the free allylic alcohol (234), which was reprotected as 
the allylic acetate (235, Scheme 3.24). 
As predicted, subsequent subjection to G2 (136) at various temperatures over 
24 hours revealed no dimerization of any of these type II substrates (Table 3.6, 
Entries 3, 4).  Unexpectedly, when reacted with a five-fold excess of (Z)-1,4-
dibromo-2-butene (236), a type I olefin synthesized via bromination of (Z)-2-butene-
1,4-diol, PMB-protected butenolide 200 still did not undergo cross metathesis.  Free 
allylic alcohol 234, however, underwent almost complete coupling to provide allyl 
bromide 238, while the acetate-protected alcohol (235) provided a mixture of 
products (Table 3.6, Entries 5-7). 
These findings suggest that the sterically bulky PMB protecting group might 
be inhibiting the reactivity of the butenolide fragment altogether.  Current studies are 
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under way in the laboratory to investigate the efficacy of a cross metathesis between 
alternative butenolide fragments 234 or 235, and dihydropyran dimer 233. 
 
Scheme 3.24 Reactivity studies of butenolides towards cross-dimerization. 
5. Efforts toward the Completion of Pyranicin 
While optimization of the RCM/CM sequence continued, all that remained 
between coupled product 198 and pyrancin (1) was the reduction of the olefins not 
present in the final product, and removal of the protecting groups.  In the total 
syntheses of annonaceous acetogenin natural products, the reduction of olefinic and 
acetylenic moieties not present in the target molecule is typically affected by 
selective reduction with Wilkinson’s catalyst21,86 or tosyldiimide.22,87  These unusual 
reduction conditions have demonstrated selective reduction of more electron rich 
olefins to avoid overreduction of the conjugated butenolide olefin in these natural 
products.  However, in the present system, reduction with hydrogen in the presence 
of Wilkinson’s catalyst did not give consistent results, often furnishing the desired 
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product mixed with a significant amount of fully-reduced byproduct 241 (Scheme 
3.25). 
 
Scheme 3.25 Completion of pyranicin. 
Accordingly, after examining numerous diimide sources and stoichiometries, 
bases, solvents, and temperatures, the best results for the ensuing reduction were 
accomplished by adding 500 equivalents of sodium acetate in water to a solution of 
400 equivalents of tosyldiimide and unsaturated intermediate 198 in refluxing 
dimethoxyethane (DME). 
Because the resultant unsaturated products in these reactions are usually 
difficult to remove from the extreme excess of diimide byproducts, the reaction 
solution is typically stirred with 1 M HCl/MeOH to remove the byproducts.  The yield 
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and mass recovery after this traditional quench were suspiciously low, and 
envisioned to be due to concomitant acidic cleavage of the silyl protecting groups.  
To confirm this prediction, to a small amount of isolated protected tetraol 240 was 
added a solution of 10% HCl in MeOH.  After stirring for eight hours, a very polar 
spot was isolated, and its identity as the partially deprotected tetraol 242 was 
confirmed by both 1H NMR analysis and mass spectrometry.  Unfortunately, due to 
the currently unresolved issues of the preceding cross metathesis, not enough 
coupled product has been procured to date to obtain accurate and acceptable yields 
and characterization data. 
Following optimization of the endgame strategy, it is expected that acidic 
removal of both the PMB and benzyl protecting groups should provide pyranicin (1).  
Studies are currently underway towards enhancing the efficiency of the cross 
metathesis and selective reduction reactions. 
Alternatively, if the ring-closing metathesis/cross metathesis strategy cannot 
be optimized, a third route has been proposed, that would bring the eastern and 
western fragments of pyranicin together via a late-stage Sonogashira coupling 
reaction,88 previously proven to be successful in our laboratory towards the 
preparation of (-)-mucocin 143.22  The divergence of such a strategy from the current 
approach is minimal, and thus allows for the recycling of substrates that have been 
previously prepared (Figure 3.11). 
Accordingly, enyne 243 could be accessed via a Sonogashira cross-coupling 
reaction between alkyne 244 and vinyl iodide 245.  The alkyne would be accessed  
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Figure 3.11 Sonogashira approach to pyranicin. 
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via a familiar glycolate aldol/ring-closing metathesis strategy employing glycolylimide 
91 and aldehyde 246.  The aldehyde, in turn, could be synthesized from (S)-benzyl 
glycidyl ether, in a similar manner as aldehyde 202.  The vinyl iodide, on the other 
hand, is predicted to be accessible from TBDPS-protected acid 204, following a 
similar protocol as previously employed. 
 Several strategies have been investigated towards the asymmetric total 
synthesis of pyranicin.  The glycolate aldol/RCM strategy has proven to be an 
efficient technique for the synthesis of the diverse medium-size ring ethers common 
to this family of natural products.  Furthermore, the glycolate alkylation/relay ring-
closing metathesis has demonstrated high effectiveness in the construction of the γ-
methybutenolide embedded in these natural products.  Studies are currently 
underway to further uncover a technique that is able to couple the eastern and 
western fragments in a convergent manner. 
  
 92 
 
REFERENCES 
(1) Arundale, E.; Mikeska, L. A. Chem. Rev. 1952, 52, 505. 
(2) Jasti, R.; Rychnovsky, S. D. Org. Lett. 2006, 8, 2175. 
(3) Clarke, P. A.; Santos, S. Eur. J. Org. Chem. 2006, 2045. 
(4) Strand, D.; Norrby, P.-O.; Rein, T. J. Org. Chem. 2006, 71, 1879. 
(5) Strand, D.; Rein, T. Org. Lett. 2005, 7, 199. 
(6) Betancort, J. M.; Martin, V. S.; Padron, J. M.; Palazon, J. M.; Ramirez, M. A.; Soler, 
M. A. J. Org. Chem. 1997, 62, 4570. 
(7) Schneider, C.; Schuffenhauer, A. Eur. J. Org. Chem. 2000, 73. 
(8) Takahashi, S.; Kubota, A.; Nakata, T. Org. Lett. 2003, 5, 1353. 
(9) Takahashi, S.; Ogawa, N.; Koshino, H.; Nakata, T. Org. Lett. 2005, 7, 2783. 
(10) Lee, E.; Choi, S. J.; Kim, H.; Han, H. O.; Kim, Y. K.; Min, S. J.; Son, S. H.; Lim, S. M.; 
Jang, W. S. Angew. Chem. Int. Ed. 2002, 41, 176. 
(11) Song, H. Y.; Joo, J. M.; Kang, J. W.; Kim, D.-S.; Jung, C.-K.; Kwak, H. S.; Park, J. 
H.; Lee, E.; Hong, C. H.; Jeong, S. W.; Jeon, K.; Park, J. H. J. Org. Chem. 2003, 68, 
8080. 
(12) Hattori, Y.; Furuhata, S.-I.; Okajima, M.; Konno, H.; Abe, M.; Miyoshi, H.; Goto, T.; 
Makabe, H. Org. Lett. 2008, 10, 717. 
(13) Crimmins, M. T.; Emmitte, K. A. Synthesis 2000, 899. 
(14) Fujiwara, K.; Awakura, D.; Tsunashima, M. J. Org. Chem. 1999, 64, 2616. 
(15) Crimmins, M. T.; Tabet, E. A. J. Am. Chem. Soc. 2000, 122, 5473. 
(16) Crimmins, M. T.; Choy, A. L. J. Am. Chem. Soc. 1999, 121, 5653. 
(17) Crimmins, M. T.; She, J. Synlett 2004, 1371. 
(18) Crimmins, M. T.; Emmitte, K. A. J. Am. Chem. Soc. 2001, 123, 1533. 
(19) Crimmins, M. T.; Emmitte, K. A.; Choy, A. L. Tetrahedron 2002, 58, 1817. 
(20) Crimmins, M. T.; Ellis, J. M. J. Am. Chem. Soc. 2005, 127, 17200. 
(21) Crimmins, M. T.; She, J. J. Am. Chem. Soc. 2004, 126, 12790. 
(22) Crimmins, M. T.; Zhang, Y.; Diaz, F. A. Org. Lett. 2006, 8, 2369. 
(23) Crimmins, M. T.; McDougall, P. J. Org. Lett. 2003, 5, 591. 
 93 
 
(24) Crimmins, M. T.; Cleary, P. A. Heterocycles 2003, 61, 87. 
(25) Crimmins, M. T.; McDougall, P. J.; Ellis, J. M. Org. Lett. 2006, 8, 4079. 
(26) Crimmins, M. T.; McDougall, P. J.; Emmitte, K. A. Org. Lett. 2005, 7, 4033. 
(27) Crimmins, M. T.; Zuccarello, J. L.; Cleary, P. A.; Parrish, J. D. Org. Lett. 2006, 8, 
159. 
(28) Mancuso, A. J.; Huang, S.-L.; Swern, D. J. Org. Chem. 1978, 43, 2480. 
(29) Baldwin, J. E.; Claridge, T. D. W.; Culshaw, A. J.; Heupel, F. A.; Lee, V.; Spring, D. 
R.; Whitehead, R. C. Chem. Eur. J. 1999, 5, 3154. 
(30) Cloke, J. B.; Pilgrim, F. J. J. Am. Chem. Soc. 1939, 61, 2667. 
(31) Finkelstein, H. Chem. Ber. 1910, 43, 1528. 
(32) Lespieau, R.; Bourguel, M. In Organic Syntheses; Blatt, A. H., Ed.; John Wiley & 
Sons, Inc.: New York, 1941; Vol. Coll. Vol. 1, p 203. 
(33) Villieras, J.; Rambaud, M. In Organic Syntheses; Freeman, J. P., Ed.; John Wiley & 
Sons, Inc.: New York, 1993; Vol. Coll. Vol. 8, p 265. 
(34) Villieras, J.; Rambaud, M. Synthesis 1982, 924. 
(35) Dunn, P. J.; Hughes, M. L.; Searle, P. M.; Wood, A. S. Org. Process Res. Dev. 2003, 
7, 244. 
(36) Mitsunobu, O. Synthesis 1981, 1. 
(37) Hoye, T. R.; Jeffrey, C. S.; Tennakoon, M. A.; Wang, J.; Zhao, H. J. Am. Chem. Soc. 
2004, 126, 10210. 
(38) Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953. 
(39) Chatterjee, A. K.; Choi, T.-L.; Sanders, D. P.; Grubbs, R. H. J. Am. Chem. Soc. 
2003, 125, 11360. 
(40) Lang, R. W.; Hansen, H.-J. In Organic Syntheses; Freeman, J. P., Ed.; John Wiley & 
Sons, Inc.: 1990; Vol. Coll. Vol. 7, p 232. 
(41) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. Bull. Chem. Soc. Japan 
1979, 52, 1989. 
(42) Sanford, M. S.; Love, J. A.; Grubbs, R. H. J. Am. Chem. Soc. 2001, 123, 6543. 
(43) Trnka, T. M.; Grubbs, R. H. Acc. Chem. Res. 2001, 34, 18. 
(44) Hong, S. H.; Sanders, D. P.; Lee, C. W.; Grubbs, R. H. J. Am. Chem. Soc. 2005, 
127, 17160. 
 94 
 
(45) Nosse, B.; Schall, A.; Jeong, W. B.; Reiser, O. Adv. Synth. Catal. 2005, 347, 1869. 
(46) Anand, N. K.; Carreira, E. M. J. Am. Chem. Soc. 2001, 123, 9687. 
(47) Sasaki, H.; Boyall, D.; Carreira, E. M. Helv. Chim. Acta 2001, 84, 964. 
(48) Frantz, D. E.; Fassler, R.; Carreira, E. M. J. Am. Chem. Soc. 2000, 122, 1806. 
(49) Oppolzer, W.; Radinov, R. N. Tetrahedron 1991, 32, 5777. 
(50) Watts, C. C.; Thoniyot, P.; Hirayama, L. C.; Romano, T.; Singaram, B. Tetrahedron: 
Asymmetry 2005, 16, 1829. 
(51) Noyori, R.; Yamakawa, M. J. Am. Chem. Soc. 1995, 117, 6327. 
(52) Noyori, R.; Kitamura, M.; Okada, S.; Suga, S. J. Am. Chem. Soc. 1989, 111, 4028. 
(53) Noyori, R.; Kitamura, M.; Oka, H. Tetrahedron 1999, 55, 3605. 
(54) Noyori, R.; Kitamura, M.; Oka, H.; Suga, S. J. Am. Chem. Soc. 1998, 120, 9800. 
(55) Milner, E. E., University of North Carolina, 2007. 
(56) Boyall, D.; Lopez, F.; Sasaki, H.; Frantz, D. E.; Carreira, E. M. Org. Lett. 2000, 2, 
4233. 
(57) Jiang, B.; Chen, Z.; Tang, X. Org. Lett. 2002, 4, 3451. 
(58) Jiang, B.; Si, Y.-G. Adv. Synth. Catal. 2004, 346, 669. 
(59) Reber, S.; Knopfel, T. F.; Carreira, E. M. Tetrahedron 2003, 59, 6813. 
(60) Jiang, B.; Chen, Z.; Xiong, W. Chem. Commun. 2002, 1524. 
(61) Pini, D.; Mastantuono, A.; Salvadori, P. Tetrahedron: Asymmetry 1994, 5, 1875. 
(62) Chen, Z.; Xiong, W.; Jiang, B. Chem. Commun. 2002, 2098. 
(63) Smith, A. B., III; Kim, D.-S. Org. Lett. 2004, 6, 1493. 
(64) Smith, A. B., III; Kim, D.-S. J. Org. Chem. 2006, 71, 2547. 
(65) Lu, G.; Li, Y.-M.; Li, X.-S.; Chan, A. S. C. Coord. Chem. Rev. 2005, 249, 1736. 
(66) Ni, M.; Wang, R.; Han, Z.-J.; Mao, B.; Da, C.-S.; Liu, L.; Chen, C. Adv. Synth. Catal. 
2005, 247, 1659. 
(67) Gao, G.; Xie, R.-G.; Pu, L. Proc. Nat. Acad. Sci. 2004, 101, 5417. 
(68) Gao, G.; Moore, D.; Xie, R.-G.; Pu, L. Org. Lett. 2002, 4, 4143. 
(69) Cozzi, P. G.; Hilgraf, R.; Zimmermann, N. Eur. J. Org. Chem. 2004, 4095. 
 95 
 
(70) Kirkham, J. E. D.; Courtney, T. D. L.; Lee, V.; Baldwin, J. E. Tetrahedron 2005, 61, 
7219. 
(71) Bennet, M. A.; Huang, T. N.; Matheson, T. W.; Smith, A. K. Inorg. Synth. 1982, 21, 
74. 
(72) Tietze, L. F.; Zhou, Y.; Topken, E. Eur. J. Org. Chem. 2000, 2247. 
(73) Haak, K.-J.; Hashiguchi, S.; Akio, F.; Ikariya, F.; Noyori, R. Angew. Chem. Int. Ed. 
1997, 36, 285. 
(74) Matsumura, K.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc. 1997, 119, 
8738. 
(75) Corey, E. J.; Bakshi, R. K.; Shibata, S. J. Am. Chem. Soc. 1987, 109, 5551. 
(76) Corey, E. J.; Bakshi, R. K.; Shibata, S.; Chen, C.-P.; Singh, V. K. J. Am. Chem. Soc. 
1987, 109, 7925. 
(77) Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K.-
S.; Kwong, H.-L.; Morikawa, K.; Wang, Z.-M.; Xu, D.; Zhang, X.-L. J. Org. Chem. 
1992, 57, 2768. 
(78) Dale, J. A.; Dull, D. L.; Mosher, H. S. J. Org. Chem. 1969, 34, 2543. 
(79) Schaus, S. E.; Brandes, B. D.; Larrow, J. F.; Tokunaga, M.; Hansen, K. B.; Gould, A. 
E.; Furrow, M. E.; Jacobsen, E. N. J. Am. Chem. Soc. 2002, 124, 1307. 
(80) Nielsen, L. P. C.; Stevenson, C. P.; Blackmond, D. G.; Jacobsen, E. N. J. Am. Chem. 
Soc. 2004, 126, 1360. 
(81) Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155. 
(82) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Angew. Chem. Int. Ed. 2005, 44, 4490. 
(83) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2000, 
122, 8168. 
(84) Hong, S. H.; Day, M. W.; Grubbs, R. H. J. Am. Chem. Soc. 2004, 126, 7414. 
(85) Hong, S. H.; Wenzel, A. G.; Salguero, T. T.; Day, M. W.; Grubbs, R. H. J. Am. Chem. 
Soc. 2007, 129, 7961. 
(86) Osborn, J. A.; Jardine, F. H.; Young, J. F.; Wilkinson, G. J. Chem. Soc. A 1966, 
1711. 
(87) Marshall, J. A.; Chen, M. J. Org. Chem. 1997, 62, 5996. 
(88) Sonogashira, R. K.; Tohda, Y.; Hagihara, N. Tetrahedron Lett. 1975, 12, 4467. 
 
  
 
EXPERIMENTAL 
Materials and Methods: General. Infrared (IR) spectra were obtained using a 
JACSO FT/IR 460-plus and a Nicolet Magna-IR 560 instruments. Proton and carbon 
nuclear magnetic resonance (1H and 13C NMR) spectra were recorded on the 
following instruments: Bruker model DRX 400 (1H at 400 MHz; 13C at 100 MHz) and 
Bruker model DRX 500 (1H at 500 MHz, 13C at 125 MHz). Chemical shifts are 
reported in ppm with residual undeuterated solvent peaks as internal reference for 
1H NMR: CHCl3 (7.24) and deuterated solvent shifts for 13C NMR: CDCl3 (77.0). 
Multiplicities are reported as (s) singlet, (d) doublet, (t) triplet, (q) quartet and (m) 
multiplet. Coupling constants (J) are given in Hz. Optical rotations were determined 
using a JASCO P1010 polarimeter. Mass spectra were obtained using a Micromass 
Quattro II (triple quad) instrument with nanoelectrospray ionization. Characterization 
data for known compounds is not reported herein but can alternatively be found in 
the literature.  Thin layer chromatography (TLC) was conducted on silica gel 60 F254 
TLC plates purchased from Sorbent Technologies, Inc. Flash chromatography was 
carried out using silica gel (60 Å, 40 to 63 μm) purchased from Sorbent 
Technologies, Inc. Diethyl ether (Et2O), tetrahydrofuran (THF), dichloromethane 
(CH2Cl2) and toluene (PhCH3) were dried by passing through a column of neutral 
alumina under nitrogen immediately prior to use. Alkylamines and benzene were 
distilled from calcium hydride immediately prior to use. Anhydrous N,N-
dimethylformamide (DMF) was purchased from Aldrich chemical company in 1L 
Sure/SealTM bottles. Pivaloyl chloride was distilled and stored over 4 Å molecular 
sieves.  BF3•OEt2 was distilled immediately prior to use.  Phosphonium salts were 
pre-dried via azeotrope in toluene.  All other reagents and solvents were used as 
received from the manufacturer. All air and water sensitive reactions were performed 
in flasks, flame dried under a positive flow of argon or vacuum, and conducted under 
argon atmosphere. 
To a flame-dried 1 L flask containing a solution of 
PCC (3.20 g, 15.0 mmol) in CH2Cl2 (250 mL) was 
add tridecanol (2.40 mL, 10.0 mmol).  The reaction was stirred for one hour under 
argon at room temperature, after which 5 g of celite was added.  Further dilution with 
hexanes provided a brown cloudy suspension which was filtered through a pad of 
celite, rinsing several times with hexanes.  Concentration under reduced pressure 
provided 1.80 g (90%) of tridecanal (94) as a colorless oil, which was immediately 
stored in benzene at -20 °C. 
H
O
94
A flame-dried three-neck 1 L round bottom flask was equipped 
with a mechanical stirrer and internal thermometer and 
charged with glycolate 91 (21.0 g, 64.9 mmol) and CH2Cl2 
(550 mL).  The solution was cooled to -78 °C in an acetone/dry ice bath, and TiCl4 
(7.48 mL, 68.2 mmol) was added via syringe.  After stirring at -78 °C for ten minutes, 
(i-Pr)2NEt (28.3 mL, 162 mmol) was added via syringe, and the solution was allowed 
to warm slowly to -40 °C.  After an additional two hours of stirring at -40 °C, the 
solution was cooled back down to -78 °C, and NMP (6.23 mL, 64.9 mmol) was 
added.  The solution remained stirring at -78 °C for an hour, after which tridecanal 
NO
O O
Bn
OBn
OH
C12H25
167
97 
 
(94, 38.7 g, 195 mmol) was added.  The solution remained at -78 °C for one hour, 
and was subsequently allowed to warm slowly to -20 °C over two hours.  The 
reaction was quenched with a saturated solution of NH4Cl at -20 °C and warmed to 
room temperature.  The organic layer was separated, and the aqueous solution 
extracted three times with CH2Cl2.  The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo.  Flash column chromatography (2.5% to 30% 
EtOAc/hexanes) provided 28.1 g (84%) of aldol adduct 167 as a colorless oil: 1H 
NMR (400 MHz, CDCl3) δ 7.393-7.266 (m, 8 H), 7.203-7.184 (m, 2 H), 5.116 (d, J = 
2.0 Hz, 1 H), 4.614 (AB, JAB = 11.6 Hz, ΔνAB = 88.8 Hz, 2 H), 4.671 (m, 1 H), 4.248-
4.166 (m, 2 H), 3.844 (m, 1 H), 3.280 (dd, J = 10.4, 3.2 Hz, 1 H), 2.748 (dd, J = 9.6, 
3.6 Hz, 1 H), 2.094 (s, 1 H), 1.641-1.420 (m, 4 H), 1.231 (m, 18 H), 0.862 (t, J = 7.2 
Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 129.4, 129.0, 128.5, 128.4, 128.2, 127.5, 
79.4, 77.2, 73.0, 72.6, 67.0, 55.7, 37.7, 34.2, 31.9, 29.6, 29.5, 29.3, 25.5, 22.7, 14.1; 
IR (film) 3450, 2924, 2853, 1781, 1709, 1455, 1390, 1212, 1114, 699 cm-1; [α]24D = 
+17.9° (c 1.22, CH2Cl2); MS (ESI) calculated for C32H24NO5 [M+Na]+: 546.3, found 
546.2. 
To a flame-dried 1 L flask containing alcohol 167 (28.1 g, 53.9 
mmol) dissolved in CH2Cl2 (500 mL) was added 2,6-lutidine 
(22.0 mL, 189 mmol) and TESOTf (15.2 mL, 67.4 mmol), 
successively.  The reaction was stirred over 12 hours at room temperature, and 
subsequently quenched with saturated NH4Cl.  The organic layer was separated, 
and the aqueous solution extracted three times with CH2Cl2.  The organic layers 
were combined, dried over Na2SO4, and concentrated in vacuo.  Flash column 
NO
O O
Bn
OBn
OTES
C12H25
168
98 
 
chromatography (0% to 5% EtOAc/hexanes) provided 33.0 g (96%) of protected 
alcohol 168 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.359-7.260 (m, 8 H), 
7.211-7.185 (m, 2 H), 5.196 (d, J = 4, 1 H), 4.614 (AB, JAB = 12.0 Hz, ΔνAB = 80.0 
Hz, 2 H), 4.527 (m, 2 H), 4.168-4.092 (m, 2 H), 4.003 (dd, J = 6.4, 3.6 Hz, 1 H), 
3.212 (dd, J = 10.4, 3.2 Hz, 1 H), 2.668 (dd, J = 10.0, 3.6 Hz, 1 H), 1.730 (m, 1 H), 
1.371 (m, 1 H), 1.236 (m, 18 H), 1.057 (m, 1 H), 0.976-0.861 (m, 12 H), 0.550 (m, 6 
H); 13C NMR (100 MHz, CDCl3) δ 135.3, 129.5, 129.0, 128.6, 128.3, 127.2, 127.4, 
77.2, 73.1, 66.6, 56.0, 33.6, 31.9, 29.7 (2), 29.6, 29.5, 29.4, 25.4, 22.7, 14.1, 6.9, 
5.0; IR (film) 2925, 2874, 2854, 1784, 1710, 1455, 1384, 1349, 1289, 1209, 1108, 
1011, 734, 699 cm-1; [α]24D = +26.8° (c 1.14, CH2Cl2); MS (ESI) calculated for 
C38H59NO5Si [M+Na]+: 660.4, found 546.3. 
A flame-dried 1 L round bottom flask was charged with 
glycolyloxazolidinone 168 (4.22 g, 6.65 mmol) and methanol 
(0.54 mL, 13.3 mmol) dissolved in Et2O (65 mL).  The flask was 
then cooled to 0 °C in an ice bath, and lithium borohydride (2.0 M in THF, 6.65 mL, 
13.3 mmol) was added dropwise via syringe.  The solution was subsequently stirred 
at 0 °C for three hours, after which Rochelle’s salt was added.  After stirring another 
hour at room temperature, the organic layer was separated, and the aqueous 
solution extracted three times with EtOAc.  The organic layers were combined, dried 
over Na2SO4, and concentrated in vacuo.  The resultant solid was isolated and 
filtered with hexanes.  Flash column chromatography of the filtrate (0% to 5% 
EtOAc/hexanes) provided 3.07 g (100%) of alcohol 169 as a colorless oil: 1H NMR 
(400 MHz, CDCl3) δ 7.321-7.287 (m, 5 H), 4.604 (d, J = 2.4 Hz, 2 H), 3.792 (m, 2 H), 
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3.648 (m, 1 H), 3.482 (m, 1 H), 2.217 (t, J = 8.0 Hz, 1 H), 1.641 (m, 1 H), 1.241 (m, 
21 H), 0.949-0.839 (m, 12 H), 0.561 (q, J = 10.4 Hz, 6 H); 13C NMR (100 MHz, 
CDCl3) δ 139.0, 128.4, 127.8, 81.2, 77.2, 72.8, 72.5, 61.6, 31.9 (2), 29.7 (2), 29.6 
(3), 29.3, 26.0, 22.7, 14.1, 6.9, 5.0; IR (film) 3441, 2925, 2875, 2854, 1456, 1239, 
1098, 1008, 741, 698 cm-1; [α]23D = +14.9° (c 1.87, CH2Cl2); MS (ESI) calculated for 
C28H52O3Si [M+Na]+: 487.4, found 487.5. 
To a flame-dried three-neck round bottom flask equipped with a stir 
bar, low temperature thermometer, and an addition funnel, was 
added oxalyl chloride (2.0 M in CH2Cl2, 34.0 mL, 67.3 mmol).  After 
dissolution in CH2Cl2 (250 mL), the solution was cooled to -78 °C in an acetone/dry 
ice bath, and DMSO (7.00 mL, 98.7 mmol) in CH2Cl2 (100 mL) was added dropwise 
via addition funnel.  After stirring 15 minutes, alcohol 169 (20.9 g, 44.9 mmol) in 
CH2Cl2 (100 mL) was added dropwise via addition funnel.  Fifteen minutes following 
the addition, neat NEt3 (38.0 mL, 270 mmol) was added dropwise at -78 °C via 
addition funnel.  After stirring another 15 minutes at this temperature, the reaction 
was allowed to warm slowly over 30 minutes to room temperature, and quenched 
with saturated NH4Cl.  The organic layer was separated, and the aqueous solution 
extracted three times with CH2Cl2.  The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo.  After flash column chromatography (5% 
EtOAc/hexanes) aldehyde 247 was immediately brought on to the ensuing 
olefination assuming 100% yield:  1H NMR (400 MHz, CDCl3) δ 9.682 (d, J = 1.2 Hz, 
1 H), 7.251-7.160 (m, 5 H), 4.549 (AB, JAB = 12.0 Hz, Δν = 104.8 Hz, 2 H), 3.853 (m, 
1 H), 3.628 (dd, J = 2.8, 1.6 Hz, 1 H), 1.635 (m, 1 H), 1.292-1.136 (m, 23 H), 0.985 
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(m, 1 H), 0.949-0.839 (m, 9 H), 0.561 (q, J = 10.4 Hz, 6 H); 13C NMR (100 MHz, 
CDCl3) δ 204.2, 137.2, 128.4, 128.3, 128.1, 84.8, 73.3, 72.7, 33.4, 31.9, 29.6 (2), 
29.5 (2), 29.3, 25.5, 22.6, 14.1, 6.7, 4.8; IR (film) 2953, 2925, 2875, 2854, 1735, 
1456, 1378, 1239, 1115, 1093, 1007, 741, 698 cm-1; [α]26D = -1.1 (c 1.48, CH2Cl2); 
MS (ESI) calculated for C28H50O3Si [M+H]+: 463.4, found 463.4. 
Methyl triphenylphosphonium bromide (64.1 g, 180 mmol) was 
dried via azeotrope in toluene (200 mL x 3) in a flame-dried 1 L 
round bottom flask equipped with a Dean-Stark trap.  Upon cooling 
to room temperature, the salt was redissolved in THF (125 mL), and potassium t-
butoxide (95%, 15.9 g, 134 mmol) in THF (125 mL) was added via cannula.  The 
canary yellow suspension stirred at room temperature for an hour, after which 
aldehyde 247 (19.0 g, 41.4 mmol) in THF (250 mL) was added via cannula.  After 
stirring at room temperature for 12 hours, the yellow reaction mixture was quenched 
with saturated NH4Cl.  After dilution with EtOAc, the organic layer was separated, 
and the aqueous solution extracted three times with EtOAc.  The organic layers 
were combined, dried over Na2SO4, and concentrated in vacuo.  Flash column 
chromatography (100% hexanes) provided 16.9 g (82% over two steps) of olefin 170 
as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.231-7.155 (m, 5 H), 5.713 (m, 1 H), 
5.213-5.151 (m, 2 H), 4.408 (AB, JAB = 12. 0 Hz, Δν = 96.8 Hz, 2 H), 3.604 (dd, J = 
4.8 Hz, 0.4 Hz, 2 H), 1.467 (m, 1 H), 1.162 (m, 21 H), 0.864-0.773 (m, 12 H), 0.462 
(q, J = 8.0 Hz, 6 H); 13C NMR (100 MHz, CDCl3) δ 138.8, 135.4, 128.2, 127.7, 127.3, 
118.2, 83.1, 74.4, 70.3, 32.8, 31.9, 29.8, 29.7 (2), 29.6, 29.4, 25.6, 22.7, 14.1, 6.9, 
5.0; IR (film) 2953, 2925, 2875, 2853, 1461, 1110, 1089, 1066, 1007, 924, 732, 694 
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cm-1; [α]26D = +7.61 (c 1.29, CH2Cl2); MS (ESI) calculated for C29H52O2Si [M+Na]+: 
483.4, found 483.4. 
To a polyurethane bottle charged with stir bar and MeCN (120 mL) 
was added protected alcohol 170 (5.69 g, 12.3 mmol).  Aqueous HF 
(40%, 1 mL) was added via pipet, and after five minutes the reaction 
was quenched with saturated NaHCO3.  EtOAc was added and the organic layer 
separated.  The aqueous layer was extracted three times with EtOAc.  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo.  Flash 
column chromatography (0% to 5% EtOAc/hexanes) provided 4.33 g (100%) of 
alcohol 171 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.350-7.260 (m, 5 H), 
5.710 (m, 1 H), 5.366-5.290 (m, 2 H), 4.475 (AB, JAB = 11.2 Hz, Δν = 106.4 Hz, 2 H), 
3.590-3.508 (m, 2 H), 2.630 (d, J = 2.8 Hz, 1 H), 1.448-1.231 (m, 22 H), 0.859 (t, J = 
6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 138.1, 135.3, 128.4, 127.9, 127.7, 120.1, 
84.5, 73.4, 70.3, 32.5, 31.9, 29.6 (3), 29.3, 25.5, 22.7, 14.1; IR (film) 3472, 2924, 
2853, 1455, 1084, 1069, 1028, 993, 929, 733, 698 cm-1; [α]26D = -12.7 (c 0.87, 
CH2Cl2); MS (ESI) calculated for C23H38O2 [M+NH4]+: 364.3, found 364.3. 
BnO
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Sodium hydride (60% dispersion in mineral oil, 3.5 g, 87.7 
mmol) was washed three times with hexanes (20 mL) under 
argon in a flame-dried 100 mL round bottom flask.  The flask 
was subsequently charged with THF (20 mL), and the septum replaced with an 
addition funnel.  The resulting suspension was cooled to 0 °C in an ice water bath, 
and bromoacetic acid (4.47 g, 32.1 mmol) in THF (7.5 mL) was added dropwise via 
addition funnel.  After stirring at 0 °C for 30 minutes, alcohol 171 (10.1 g, 29.2 mmol) 
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in DMF (15 mL) was added dropwise via addition funnel.  The solution remained 
stirring at 0 °C for 30 minutes, and was subsequently allowed to warm to room 
temperature where it stirred for an additional twelve hours.  The solution was cooled 
back down to 0 °C, and EtOAc (20 mL) was added, followed by a slow quench with 
H2O.  The organic layer was separated, and the aqueous layer was acidified to pH 2 
by addition of 6 M aqueous H2SO4, and then extracted three times with EtOAc.  The 
organic layers were combined, dried over Na2SO4, and concentrated in vacuo.  
Flash column chromatography (0% to 75% EtOAc/hexanes) provided 10.4 g (88%) 
of glycolic acid 172 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.359-7.240 (m, 
5 H), 5.622 (m, 1 H), 5.453-5.342 (m, 2 H), 4.567 (AB, JAB = 12.0 Hz, Δν = 91.2 Hz, 
2 H), 4.144 (AB, JAB = 17.2 Hz, Δν = 108.4 Hz, 2 H), 3.802 (t, J = 8.4, 1 H), 3.326 (m, 
1 H), 1.507 (m, 1 H), 1.227 (m, 22 H), 0.860 (t, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, 
CDCl3) δ 171.9, 136.3, 133.8, 128.6, 128.4, 128.2, 121.8, 84.2, 82.6, 77.2, 20.4, 
68.9, 31.9, 31.4, 29.8, 29.6 (3), 29.5, 29.4, 29.3, 24.4, 22.7, 14.1; IR (film) 3434, 
2924, 2853, 1645, 1122; [α]27D = -28.4 (c 1.09, CH2Cl2); MS (ESI) calculated for 
C25H40O4 [M+H]+: 405.3, found 405.3. 
To a flame-dried 1 L round bottom flask was added glycolic 
acid 172 (10.4 g, 25.7 mmol) and NEt3 (3.90 mL, 27.8 
mmol) in THF (150 mL).  The solution was cooled to -78 °C 
in an acetone/dry ice bath, and pivaloyl chloride (3.16 mL, 
25.7 mmol) was added dropwise via syringe.  After stirring for 15 minutes at that 
same temperature, the solution was warmed to 0 °C, stirred for an hour, and cooled 
back down to -78 °C.  In a separate flame-dried three-neck 500 mL round bottom 
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flask, equipped with low temperature thermometer and addition funnel, 
oxazolidinone 173 (3.75 g, 21.4 mmol) was dissolved in THF (200 mL).  After cooling 
to -78 °C, n-BuLi (1.2 M in hexanes, 19.6 mL, 23.5 mmol) was added dropwise via 
addition funnel, and stirred for an extra 15 minutes at this temperature.  With both 
solutions at -78 °C, the lithiated oxazolidinone was transferred via cannula to the 
mixed anhydride.  After an additional ten minutes, the reaction mixture was allowed 
to warm slowly over three hours to 0 °C.  The solution was quenched at 0 °C with 
saturated NH4Cl and subsequently warmed to room temperature.  The organic layer 
was separated, and the aqueous solution extracted three times with EtOAc.  The 
organic layers were combined, stirred for three hours with 0.1N NaOH, dried over 
Na2SO4, and concentrated in vacuo.  Flash column chromatography (0% to 30% 
hexanes) provided 9.93 g (85% based on recovered acid) of glycolylimide 91 as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.320-7.134 (m, 10 H), 5.778 (m, 1 H), 
5.326-5.284 (m, 2 H), 4.923 (AB, JAB = 18.0 Hz, Δν = 30.0 Hz, 2 H), 4.496 (AB, JAB = 
12.0 Hz, Δν = 85.2 Hz, 2 H), 4.602 (m, 1 H), 3.927 (t, J = 7.2 Hz, 1 H), 3.482 (m, 1 
H), 3.231 (dd, J = 10.4 Hz, 3.2 Hz, 1 H), 2.536 (dd, J = 6.8 Hz, 3.2 Hz, 1 H), 1.527-
1.240 (m, 24 H), 0.860 (t, J = 6.8 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 170.6, 
153.3, 138.7, 135.2, 129.4, 128.9. 128.3, 127.3 (3), 118.9, 83.7, 83.0, 77.2, 71.4, 
70.2, 67.1, 54.8, 37.6, 31.9, 31.2, 29.8, 29.7, 29.6, 29.3, 25.5, 22.7, 14.1; IR (film) 
3500, 3087, 3064, 3030, 2925, 2853, 1783, 1718, 1497, 1455, 1391, 1351, 1259, 
1214, 1137, 986, 929, 734, 700 cm-1; [α]21D = +47.3 (c 1.11, CH2Cl2); MS (ESI) 
calculated for C35H49NO5 [M+K]+: 602.3, found 602.3. 
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To a 500 mL Erlenmeyer flask charged with stir bar and 
hydrogen bromide (51.6 mL) was added p-methoxybenzyl 
alcohol (22.4 mL, 180 mmol) in a dropwise fashion via syringe.  The yellow solution 
stirred at room temperature for 15 minutes, after which Et2O (200 mL) was added.  
The aqueous layer was separated, and the organic layer was carefully extract twice 
with a solution of saturated NaHCO3, and once with brine.  The resultant p-
methoxybenzyl bromide (PMBBr) solution was dried over CaCl2, concentrated in 
vacuo, and dried further under low pressure.  A separate 500 mL flame-dried round 
bottom flask containing a solution of unwashed NaH (10.6 g, 264 mmol) in THF (130 
mL) was cooled to 0 °C in an ice water bath.  1-butynol (10 mL, 132 mmol), 
dissolved in DMF (20 mL), was added dropwise via syringe, and the solution was 
stirred for an additional 20 minutes at 0 °C.  Freshly prepared PMBBr (19.8 mL, 139 
mmol) was added, and the solution remained stirring at 0 °C for an hour, after which 
the reaction mixture was quenched slowly with H2O and warmed to room 
temperature.  EtOAc was added, and the organic layer was separated.  The 
aqueous layer was extracted three times with EtOAc.  The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo.  Flash column 
chromatography (0% to 30% hexanes) provided 24.6 g (98%) of alkyne 217 as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.051 (AB, JAB = 8.4 Hz, Δν = 148 Hz, 4 
H), 4.465 (s, 2 H), 3.776 (s, 3 H), 3.546 (t, J = 6.8 Hz, 2 H), 2.460 (td, J = 4.4 Hz, 2.8 
Hz, 2 H), 1.966 (t, J = 2.4 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 159.2, 130.1, 
129.2, 113.8, 81.3, 72.6, 69.2, 67.8, 55.2, 19.8; IR (film) 3292, 2935, 2863, 1612, 
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1513, 1464, 1362, 1302
calculated for C12H14O2 [M
, 
+
217
 
3
4
2 4
218
3
3
 1513, 1453, 1248, 1095, 1030, 824, 735, 695 cm-1; 
]20D = 0.00 (c 0.41, CH2Cl2); MS (ESI) calculated for C22H26O4 [M+Na]+: 377.2, 
found 377.3. 
 
1249, 1174, 1098, 1034, 823, 640 cm-1; MS (ESI) 
Na]+: 213.1, found 213.0. 
A flame-dried 500 mL round bottom flask was charged 
with alkyne  (5.70 g, 30.0 mmol) in THF (250 mL) 
and cooled to -78 °C in an acetone/dry ice bath.  n-BuLi (2.5M in hexanes, 10.9 mL, 
27.2 mmol) was added dropwise via syringe, and the solution stirred for ten minutes. 
BF •OEt (3.80 mL, 30.0 mmol) was subsequently added at -78 °C and stirred for an 
additional ten minutes.  (S)-Benzyl glycidyl ether (ent-203, 4.40 mL, 28.6 mmol) was 
added neat to the solution, which was allowed to stir for another hour at -78 °C.  The 
reaction was subsequently quenched with saturated NH Cl, diluted with EtOAc, and 
warmed to room temperature.  The organic layer was separated, and the aqueous 
solution extracted three times with EtOAc.  The organic layers were combined, dried 
over Na SO , and concentrated in vacuo.  Flash column chromatography (20% to 
40% EtOAc/hexanes) provided 8.06 g (82%) of propargyl alcohol  as a colorless 
oil: 1H NMR (400 MHz, CDCl ) δ 7.327-7.229 (m, 7 H), 6.854 (d, J = 8.4 Hz, 2 H), 
4.533 (s, 2 H), 4.443 (s, 2 H), 3.899 (m, 1 H), 3.774 (s, 3 H), 3.581-3.439 (m, 4 H), 
2.443-2.388 (m, 5 H); 13C NMR (100 MHz, CDCl ) δ 139.3, 138.0, 130.2, 129.2, 
128.4, 127.7 (2), 113.8, 79.5, 73.4, 73.0, 72.6, 69.1, 68.4, 55.2, 23.9, 20.1; IR (film) 
3440, 2928, 2853, 1714, 1613,
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A 50 mL round bottom flask charged with alkyne 218 
(300 mg, 0.846 mmol) and Raney nickel (2800 mesh, 
3.10 mL) in EtOH (8 mL) was evacuated under reduced pressure created by water 
aspirator.  Hydrogen gas was immediately introduced into the system via balloon 
and bubbled through the solvent.  The evacuation/sparging process was repeated 
one time, and the solution was subsequently allowed to stir for 12 hours at room 
temperature before it was filtered through celite with successive CH2Cl2 washes.  
The resultant filtrate was concentrated in vacuo, redissolved in CH2Cl2 and dried 
over Na2SO4.  Further concentration under reduced pressure provided diol 211 (210 
mg, 92%), containing a small amount of p-methoxybenzyl alcohol (from previous 
step), as a clear oil: 1H NMR (400 MHz, CDCl3) δ 7.036 (AB, JAB = 8.4 Hz, Δν = 
143.2 Hz, 4 H), 4.395 (s, 2 H), 4.260 (t, J = 6.4 Hz, 1 H), 3.771 (s, 3 H), 3.663-3.585 
(m, 3 H), 3.424-3.356 (m, 3 H), 2.315 (s, 2 H), 1.757 (m, 6 H); 13C NMR (100 MHz, 
CDCl3) δ 131.5, 129.2, 113.8, 113.6, 7
PMBO OH
OH
211
2.5, 72.1, 69.9, 66.8, 55.4, 55.2, 33.1, 33.0, 
29.6, 26.2, 25.3; IR (film) 3388, 2935, 2859, 1710, 1607, 1513, 1255, 1170, 1100, 
D = +1.11 (c 0.89, CH2Cl2); MS (ESI) calculated for 
C15H24O4 [M+Na] : 291.2, found 291.2. 
To a 100 mL flame-dried round bottom flask containing 
CH2Cl2 (10 mL) was added diol 211 (5.30 g, 19.8 
mmol) and NEt3 (11.0 mL, 79.0 mmol) and DMAP (480 mg, 3.95 mmol).  The 
mixture was subsequently cooled to -78 °C in an acetone/dry ice bath, and a solution 
of TrisCl (6.58 g, 21.7 mmol) dissolved in CH2Cl2 (20 mL) was added dropwise via 
syringe.  The reaction was slowly warmed to -20 °C, at which temperature it was 
1033, 848, 820 cm-1; [α]21
+
PMBO OTris
OH
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stirred over the next 12 hours in a chemical refrigerator.  The cloudy white reaction 
mixture was quenched with saturated NaHCO3 and allowed to warm to room 
temperature.  The organic layer was separated, and the aqueous layer was 
extracted three times with CH2Cl2.  The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo.  Flash column chromatography (0% to 20% 
EtOAc/hexanes) provided 8.27 g (78%) of trisylate 219 as a colorless oil: 1H NMR 
(500 MHz, CDCl3) δ 7.304 (s, 2 H), 7.104 (AB, JAB = 8.5 Hz, Δν = 179.5 Hz, 4 H), 
4.458 (s, 2 H), 4.170 (m, 2 H), 4.094 (dd, J = 7.0 Hz, 2.5 Hz, 1 H), 3.982-3.923 (m, 2 
H), 3.842 (s, 3 H), 3.462 (t, J = 6.5 Hz, 2 H), 2.958 (m, 1 H), 2.227 (s, 1 H), 1.630 (m, 
2 H), 1.498 (m, 3 H), 1.396 (m, 3 H), 1.306 (d, J = 5.5 Hz, 18 H); 13C NMR (125 
MHz, CDCl3) δ 159.0, 153.8, 150.7, 130.5, 129.2, 128.9, 123.8, 113.6, 77.2, 73.0, 
72.4, 69.8, 69.5, 55.2 (2
-1; 
22 +
(s, 3 H), 3.415 (t, J = 6.8 Hz, 2 H), 2.876 (m, 1 H), 2.717 (t, J = 4.8 Hz, 1 H), 2.433 
), 34.2, 32.6, 29.6, 29.5, 26.0, 25.0 (3), 23.5; IR (film) 2958, 
6, 1248, 1178, 1098, 1038, 971, 812, 666, 563 cm
[α] D = +3.85 (c 1.23, CH2Cl2); MS (ESI) calculated for C30H46O6S [M+Na] : 557.3, 
found 557.4. 
To a 100 mL round bottom flask containing a solution of 
trisylate 219 (8.00 g, 15.0 mmol) in methanol (30 mL) was 
added K2CO3 (4.14 g, 29.9 mmol).  After one hour the reaction was concentrated in 
vacuo, and the resulting white precipitate was filtered and rinsed thoroughly with 
hexanes.  The filtrate was concentrated at room temperature under reduced 
pressure to provide 3.54 g (95%) of epoxide 213 as a colorless oil: 1H NMR (400 
MHz, CDCl3) δ 7.043 (AB, JAB = 8.4 Hz, Δν = 144.4 Hz, 4 H), 4.404 (s, 2 H), 3.778 
2867, 1600, 1513, 1462, 134
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(dd, J = 2.8 Hz, 2.4 Hz, 1 H), 1.609-1.469 (m, 8 H); 13C NMR (100 MHz, CDCl3) δ 
129.2, 113.8, 72.5, 70.0, 55.3, 52.2, 47.0, 32.4, 29.7, 26.1, 25.8; IR (film) 2935, 
2858, 1612, 1513, 1463, 1362, -1 23
); MS (ESI) calculated for C +
 1302, 1248, 1174, 1096, 1035, 823 cm ; [α] D =       
15H22O3 [M+K] : 289.2, found 
289.1. 
Magnesium chips (1.58 g, 65.8 mmol) were placed 
in a 25 mL three-neck round bottom flask equipped 
with stir bar, condenser, and addition funnel.  The flask was subsequently flame-
dried under a positive stream of argon.  Upon cooling to room temperature, a small 
crystal of iodine was added to the reaction flask, as well as a small amount of Et2O 
(0.1 mL).  A solution of 4-bromobutene (7.59 mL, 74.8 mmol) in Et2O (15 mL) was 
added via addition funnel at a rate that was conducive to slow reflux, and was stirred 
an additional two hours following the reflux.  The resultant murky brown solution was 
diluted with Et2O (30 mL).  In a separate flame-dried 500 mL flask, copper bromide-
dimethyl sulfide complex (12.3 g, 59.8 mmol) was dissolved in Et2O (90 mL).  The 
suspension was cooled to -78 °C in an acetone/dry ice bath, and epoxide 213 (3.39 
g, 13.5 mmol) in Et2O (5 mL) was added via syringe.  After stirring for ten minutes, 
the previously prepared Grignard reagent was transferred via cannula.  The reaction 
flask was stirred at -78 °C for one hour, after which the reaction mixture was 
quenched slowly with saturated NH4Cl and warmed to room temperature.  The 
organic layer was separated, and the aqueous layer was extracted three times with 
EtOAc.  The organic layers were combined, dried over Na2SO4, and concentrated in 
vacuo.  Flash column chromatography (10% to 15% EtOAc/hexanes) provided 4.09 
-0.612 (c 0.67, CH2Cl2
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g (99%) of alcohol 214 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.041 (AB, 
JAB = 8.4 Hz, Δν = 144.8 Hz, 4 H), 5.783 (m, 1 H), 5.007-4.914 (m, 2 H), 4.402 (s, 2 
H), 3.777 (s, 3 H), 3.563 (s, 1 H), 3.411 (t, J = 6.4 Hz, 2 H), 2.040 (s, 2 H), 1.602-
1.315 (m, 13 H); 13C NMR (100 MHz, CDCl3) δ 159.1, 138.7, 130.8, 129.1, 114.5, 
113.8, 72.5, 71.7, 70.0, 55.2, 37.4, 36.9, 33.7, 29.7, 26.2, 25.4, 24.9; IR (film) 3413, 
2933, 2857, 1724, 1639, 1613,
 = +4.79 (
H O
9.1, 114.2, 113.7, 72.5, 72.1, 
70.1, 55.2, 37.1, 36.5, 33.9, 29.8, 26.4, 25.9, 25.1, 24.6, 
 1586, 1513, 1462, 1363, 1302, 1248, 1174, 1093, 
c 0.24, CH2Cl2); MS (ESI) calculated for 
C19 30 3 [M+Na] : 329.2, found 329.3. 
To a 100 mL flame-dried round bottom flask was 
added alcohol 214 (4.00 g, 13.1 mmol) dissolved in 
CH2Cl2 (13 mL).  The solution was cooled to -78 °C in an acetone/dry ice bath, and 
2,6-lutidine (5.32 mL, 45.7 mmol) and TBSOTf (3.75 mL, 16.3 mmol) were added 
successively.  The reaction mixture warmed slowly over 1.5 hours to -50 °C, and 
subsequently quenched with saturated NH4Cl.  The organic layer was separated, 
and the aqueous solution was extracted three times with CH2Cl2.  The organic layers 
were combined, dried over Na2SO4, and concentrated in vacuo to give 5.33 g (97%) 
of protected alcohol 248 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.053 (AB, 
JAB = 8.4 Hz, Δν = 145.6 Hz, 4 H), 5.788 (m, 1 H), 5.005-4.914 (m, 2 H), 4.414 (s, 2 
H), 3.787 (s, 3 H), 3.610 (t, J = 5.2 Hz, 1 H), 3.417 (t, J = 6.4 Hz, 2 H), 2.017 (d, J = 
5.6 Hz, 2 H), 1.577 (m, 2 H), 1.411-1.313 (m, 10 H), 0.865 (s, 9 H), 0.016 (s, 6 H); 
13C NMR (100 MHz, CDCl3) δ 159.1, 138.9, 130.9, 12
1037, 910, 822 cm-1; [α]21D
+
18.1, -4.5; IR (film) 2933, 
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2856, 1513, 1249, 835, 773 cm-1; [α]21D = +0.67 (c 1.01, CH2Cl2); MS (ESI) 
calculated for C25H44O3Si [M+H]+: 421.3, found 421.4. 
 A round bottom flask containing bis-protected alcohol 
 (4.56 g, 10.4 mmol) was charged with CH Cl  (47 
mL) and pH 7 buffer (5 mL).  DDQ (2.95 g, 13.0 mmol) was added in one portion, 
and the biphasic mixture stirred for 20 minutes.  The orange mixture was 
subsequently quenched slowly with an aqueous 1:1 NaHCO :Na S O  solution.  The 
organic layer was separated, and the aqueous solution was extracted three times 
with CH
248 2 2
3 2 2 3
2Cl2.  The organic layers were combined, dried over Na2SO4, and 
4
2 2 2 2
2 2
2 2
3 
quenched with saturated NH4Cl.  The organic layer was separated, and the aqueous 
HO
OTBS
249
concentrated in vacuo. 
EtOAc/hexanes) alcohol 2
 After flash column chromatography (0% to 10% 
9, in a 1:1 mixture with p-anisaldehyde, was immediately 
brought on to the ensuing oxidation assuming 100% yield. 
To a flame-dried 500 mL round bottom flask equipped 
with stir bar and addition funnel was added oxalyl 
chloride (2.0 M in CH Cl , 8.20 mL, 16.3 mmol).  After dissolution in CH Cl  (50 mL), 
the solution was cooled to -78 °C in an acetone/dry ice bath, and DMSO (1.70 mL, 
23.8 mmol) in CH Cl  (25 mL) was added dropwise via addition funnel.  After stirring 
15 minutes, all of alcohol 249 (see above) isolated from the previous reaction was 
dissolved in CH Cl  (100 mL) and added dropwise via addition funnel.  Fifteen 
minutes following the addition, neat NEt (9.00 mL, 65.0 mmol) was added dropwise 
at -78 °C via addition funnel.  After stirring another 15 minutes at this temperature, 
the reaction was allowed to warm slowly over 30 minutes to room temperature, and 
O
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solution extracted three times with CH2Cl2.  The organic layers were combined, dried 
over Na2SO4, and concentrated in vacuo.  After flash column chromatography (0% to 
5 % EtOAc/hexanes), 2.64 g of aldehyde 202 (82% over two steps) were isolated as 
To a 25 mL flame-dried round bottom flask 
was added glycolate 91 (200 mg, 0.36 mmol) 
in CH2Cl2 (2.5 mL).  The solution was cooled 
to -78 °C in an acetone/dry ice bath, and TiCl4 
(41.0 µL, 0.38 mmol) was added via syringe.  After stirring at -78 °C for ten minutes, 
(i-Pr)2NEt (0.16 mL, 0.89 mmol) was added via syringe, and the reaction mixture 
was allowed to warm slowly to -45 °C.  After an additional 12 hours of stirring at -45 
°C in a cryotrol instrument, the solution was cooled back down to -78 °C, and NMP 
(34.0 µL 0.36 mmol) was added.  The solution remained at -78 °C for another ten 
minutes, after which aldehyde 202 (200 mg, 0.67 mmol) in CH2Cl2 (1.0 mL) was 
added.  After another hour at  -78 °C the reaction mixture was warmed to -40 °C in a 
cryotrol instrument, where it stirred for an additional twelve hours.  The reaction was 
quenched with a saturated solution of NH4Cl at -40 °C and allowed to warm to room 
temperature.  The organic layer was separated, and the aqueous solution extracted 
three times with CH2Cl2.  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo.  Flash column chromatography (0% to 10% EtOAc/hexanes) 
provided 28.1 g (84%) of aldol adduct 220 as a white crystalline solid: 1H NMR (400 
MHz, CDCl3) δ 7.314-7.206 (m, 8 H), 7.006 (d, J = 7.2 Hz, 2 H), 5.740 (m, 2 H), 
5.439 (d, J = 1.6 Hz, 1 H), 5.304 (dd, J = 12.0 Hz, 1.6 Hz, 2 H), 4.997-4.906 (m, 2 
a clear oil. 
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H), 4.460 (AB, JAB = 12.8 Hz, Δν = 131.6 Hz, 2 H), 4.430 (m, 1 H), 3.974 (td, J = 29.2 
Hz, 11.2 Hz, 2 H), 3.830 (dd, J = 9.2 Hz, 2.4 Hz, 1 H), 3.730 (s, 1 H), 3.589 (m, 2 H), 
3.595 (m, 1 H), 2.015 (d, J = 6.0 Hz, 2 H), 1.633-1.243 (m, 36), 0.861 (s, 12 H), 
0.016 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 171.4, 139.0 (2), 135.6, 134.8, 129.2, 
128.8, 128.3, 127.1, 127.0, 126.3, 119.1, 114.2, 83.5, 81.0, 73.2, 72.0, 69.3, 66.7, 
55.8, 37.1, 36.9, 36.5, 34.4, 33.9, 31.9, 31.3, 29.8, 29.7, 29.6, 29.5, 29.3, 26.0, 25.9, 
25.3, 24.5, 22.6, 18.1, 14.0; IR (film) 2926, 2854, 1780, 1713, 1390, 1211, 1069, 
835, 699 cm-1; [α]21D = +15.143 (c 0.45, CH2Cl2); MS (ESI) calculated for 
To a flame-dried scintillation vial equipped 
with stir bar was added alcohol 220 (127 mg, 
0.147 mmol) dissolved in CH2Cl2 (50.0 µL).  
2,6-lutidine (86.0 µL, 0.736 mmol) and 
TESOTf (68.0 µL, 0.295 mmol) were added successively.  The reaction mixture was 
stirred over 12 hours at room temperature, and subsequently quenched with 
saturated NH4Cl.  The organic layer was separated, and the aqueous solution was 
extracted three times with CH2Cl2.  The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo.  Flash column chromatography (0% to 5% 
EtOAc/hexanes) provided 133 mg (93%) of protected alcohol 250 as a clear oil: 1H 
NMR (400 MHz, CDCl3) δ 7.297-7.164 (m, 8 H), 7.014 (d, J = 7.2 Hz, 2 H), 5.721 (m, 
2 H), 5.525 (d, J = 3.6 Hz, 1 H), 5.242-5.197 (m, 2 H), 4.957-4.866 (m, 2 H), 4.561 
(d, J = 12.8 Hz, 1 H), 4.296 (m, 2 H), 3.905-3.835 (m, 4 H), 3.576 (s, 1 H), 3.460 (s, 
1 H), 3.082 (d, J = 10.0 Hz, 1 H), 1.976 (d, J = 5.2 Hz, 2 H), 1.713 (m, 2 H), 1.562-
C52H83NO7Si [M+Na]+: 884.6, found 884.6. 
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1.198 (m, 36 H), 0.844 (m, 18 H), 0.530 (q, J = 8.0 Hz, 6 H), -0.022 (s, 6 H); 13C 
NMR (100 MHz, CDCl3) δ 171.8, 153.3, 139.2, 139.0, 135.9, 135.2, 129.4, 128.8, 
128.3, 128.2, 127.1, 126.9, 126.7, 118.4, 114.3, 83.5, 83.0, 80.1, 73.9, 72.1, 69.7, 
66.3, 56.4, 37.2, 36.6, 33.9, 33.2, 31.9, 31.0, 29.8, 29.7 (3), 29.3, 26.4, 26.0, 25.7, 
24.6, 22.7, 18.1, 14.1, 6.9, 5.0, -4.4 (2); IR (film) 2927, 2855, 1785, 1711, 1456, 
1253, 1103, 835, 773, 733, 699 cm-1 20
: 998.7, found 998.7. 
; [α] D = +27.10 (c 1.38, CH2Cl2); MS (ESI) 
A flame-dried 25 mL round bottom flask was 
charged with glycolyloxazolidinone 250 (770 
mg, 0.79 mmol) and methanol (60 µL, 1.58 
mmol) dissolved in Et2O (8 mL).  The flask 
was then cooled to 0 °C in an ice bath, and lithium borohydride (2.0 M in THF, 0.79 
mL, 1.58 mmol) was added dropwise via syringe.  The solution was subsequently 
stirred at -20 °C in a chemical refrigerator for three hours, after which Rochelle’s salt 
was added.  After stirring another hour at room temperature, the organic layer was 
separated, and the aqueous solution extracted three times with EtOAc.  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo.  The resultant 
solid was isolated and filtered with hexanes.  Flash column chromatography of the 
filtrate (0% to 5% EtOAc/hexanes) provided 558 mg (88%) of alcohol 221 as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.338-7.251 (m, 5 H), 5.845-5.630 (m, 2 
H), 5.346-5.254 (m, 2 H), 4.999-4.906 (m, 2 H), 4.499 (AB, JAB = 12.0 Hz, 86.4 Hz, 2 
H), 3.784 (t, J = 7.6 Hz, 1 H), 3.728-3.462 (m, 6 H), 2.014 (d, J = 5.6 Hz, 2 H), 1.409-
1.229 (m, 36 H), 0.931 (t, J = 8.0 Hz, 9 H), 0.865 (s, 9 H), 0.572 (q, J = 8.0 Hz, 6 H), 
calculated for C58H97NO7Si [M+Na]+
O
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0.016 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 138.9, 137.8, 135.2, 128.3, 128.3, 
127.9, 127.6, 119.8, 114.2, 83.5, 83.1, 82.0, 73.2, 72.1, 70.2, 61.8, 37.2, 36.5, 33.9, 
32.1, 31.9, 31.6, 29.9, 29.6 (2), 29.3, 26.9, 25.9, 25.6, 24.9, 24.6, 22.6, 18.1, 14.0. 
6.8, 5.1, -4.4, -4.5; IR (film) 3464, 2927, 2855, 1462, 1254, 1069, 910, 835, 774, 732 
cm-1; [α]22D = +8.61 (c 1.50, CH2Cl2); MS (ESI) calculated for C +48H90O5Si2 [M+Na] : 
To a 25 mL round bottom flask was added 
alcohol 221 (360 mg, 0.45 mmol) and 
CH2Cl2 (9 mL).  Sodium bicarbonate (376 
mg, 4.49 mmol) was introduced into the 
reaction mixture, followed by DMP (437 mg, 1.03 mmol).  The white suspension 
stirred at room temperature for an hour, after which it was quenched with an 
aqueous solution of 1:1 saturated NaHCO3:saturated Na2S2O3.  The organic layer 
was separated, and the aqueous solution extracted three times with CH2Cl2.  The 
organic layers were combined, dried over Na2SO4, and concentrated in vacuo.  
Flash column chromatography (0% to 5% EtOAc/hexanes) provided 353 mg (98%) 
of aldehyde 251 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 9.656 (d, J = 1.2 Hz, 
1 H), 7.286-7.226 (m, 5 H), 5.825-5.620 (m, 2 H), 5.308-5.246 (m, 2 H), 4.992-4.899 
(m, 2 H), 4.370 (AB, JAB = 11.6 Hz, 99.6 Hz, 2 H), 3.996 (d, J = 4.4 Hz, 1 H), 3.832 
(m, 2 H), 3.587 (m, 1 H), 3.285 (m, 1 H), 2.002 (d, J = 6.4 Hz, 2 H), 1.700 (m, 1 H), 
1.432-1.225 (m, 36 H), 0.904 (t, J = 8.0 Hz, 9 H), 0.852 (s, 9 H), 0.559 (q, J = 8 Hz, 6 
H), 0.001 (d, J = 2.0 Hz, 6 H); 13C NMR (100 MHz, CDCl3) δ 203.9, 138.9, 138.3, 
135.9, 128.2, 127.8, 127.4, 119.1, 114.3, 87.2, 84.0, 83.1, 73.6, 72.0, 70.2, 37.1, 
825.6, found 825.7. 
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36.5, 33.9, 33.0, 31.9, 31.2, 29.6 (2), 29.3, 26.2, 25.9, 25.6, 25.3, 24.5, 22.6, 18.1, 
14.0, 6.8, 5.0, -4.5; IR (film) 2927, 2855, 1736, 1462, 1376, 1254, 1071, 1005, 910, 
835, 773, 731 cm-1; [α]22  = +19.36 (D
C48H88O5Si2 [M+Na]+: 823.6, found 823.7. 
c 1.45, CH2Cl2); MS (ESI) calculated for 
Methyl triphenylphosphonium bromide (640 
mg, 1.79 mmol) was dried via azeotrope in 
toluene (5 mL x 3) on a rotary evaporation 
system.  Upon cooling to room temperature, 
the salt was redissolved in THF (3 mL), and potassium t-butoxide (95%, 159 g, 1.34 
mmol) in THF (1 mL) was added via syringe.  The canary yellow suspension stirred 
at room temperature for an hour, after which aldehyde 251 (353 mg, 41.4 mmol) in 
THF (1 mL) was added via syringe.  After stirring at room temperature for 12 hours, 
the yellow reaction mixture was quenched with saturated NH4Cl and diluted with 
EtOAc.  The organic layer was separated, and the aqueous solution extracted three 
times with EtOAc.  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo.  Flash column chromatography (0% to 5% EtOAc/hexanes) 
provided 313 mg (87%) of triene 199 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 
7.346-7.298 (m, 5 H), 5.819-5.743 (m, 3 H), 5.272-5.133 (m, 4 H), 5.001-4.909 (m, 2 
H), 4.472 (AB, JAB = 12.0 Hz, 80.8 Hz, 2 H), 3.783 (m, 2 H), 3.669-3.591 (m, 2 H), 
3.407 (t, J = 3.2 Hz, 1 H), 2.013 (d, J = 5.6 Hz, 2 H), 1.551 (m, 2 H), 1.391 (m, 3 H), 
1.241 (s, 32 H), 0.937 (t, J = 8.0 Hz, 9 H), 0.864 (s, 9 H), 0.587 (q, J = 8.0 Hz, 6 H), 
0.012 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 139.0, 138.9, 135.9, 135.5, 128.2, 
127.6, 127.3, 117.9, 117.4, 114.2, 83.5, 81.8, 79.6, 73.8, 72.2, 70.6, 37.2, 36.5, 
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33.9, 32.0, 31.9, 30.3, 29.9, 29.7 (2), 29.3, 26.3, 25.9, 25.8, 25.6, 24.6, 22.7, 18.1, 
14.0, 6.9, 5.2, -4.4, -4.5; IR (film) 2927, 2855, 1462, 1253, 1071, 1005, 923, 835, 
773, 732 cm-1; [ 23
: 821.6, found 821.7. 
of ethyl-2-
(hydroxymethyl)acrylate  (84%) as a colorless oil (bp = 85 °C, 8 mm Hg), which 
was immediately stored in CH
α] D = +23.21 (c 1.07, CH2Cl2); MS (ESI) calculated for C49H90O4Si2 
To a 250 mL three-neck round bottom flask equipped with stir bar, 
internal thermometer, addition funnel and reflux condenser was 
added H2O (40 mL), paraformaldehyde (95%, 17.2 g, 544 mmol), 
and 1 N H3PO4 (1.53 mL).  The aqueous mixture was stirred at 100 °C for 1.5 hours 
until all the solids had dissolved and the solution turned clear.  The flask was then 
cooled to room temperature, triethylphosphonoacetate (27.0 mL, 136 mmol) was 
added, and the flask contents were stirred for five minutes.  Next, while maintaining 
the internal temperature between 35 °C and 40 °C by submerging the reaction 
vessel in a tepid water bath, a solution of K2CO3 (20.7 g, 150 mmol) in H2O (22 mL) 
was added dropwise via addition funnel, and stirred for an additional five minutes at 
this temperature.  The water bath was subsequently removed, and rapidly replaced 
with a 0 °C ice water bath.  The reaction mixture was immediately diluted with Et2O 
(40 mL) followed by brine (40 mL).  The organic layer was separated, and the 
aqueous solution extracted three times with Et2O.  The organic layers were 
combined, washed twice with brine, dried over Na2SO4, and concentrated in vacuo.  
Purification by vacuum distillation afforded 14.85 g 
HO
[M+Na]+
O
OEt
110
110
2Cl2 at 0 °C to prevent polymerization. 
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To a flame-dried 1 L flask containing ethyl-2-
(hydroxymethyl)acrylate 110 (24.3 g, 187 mmol) dissolved in 
CH2Cl2 (600 mL) was added imidazole (32.0 g, 467 mmol) and 
TBSCl (30.5 g, 233 mmol), successively, after which a white solid precipitated from 
the solution.  The reaction mixture was stirred at room temperature for two hours, 
and subsequently quenched with saturated NaHCO3.  The organic layer was 
separated, and the aqueous solution extracted three times with CH2Cl2.  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo.  Flash 
column chromatography (0% to 5% EtOAc/hexanes) provided 44.9 g (100%) of 
protected alcohol 112 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 6.226 (q, J = 
2.0 Hz, 1 H), 5.874 (q, J = 2.0 Hz, 1 H), 4.343 (t, J = 2.0 Hz, 2 H), 4.189 (q, J = 7.2 
Hz, 2 H), 1.276 (t, J = 7.2 Hz, 3 H), 0.895 (s, 9 H), 0.058 (s, 6 H); 13C NMR (100 
MHz, CDCl3) δ 165.9, 140.0, 123.5, 61.5, 60.5, 25.9, 18.3, 14.2, -5.5; IR (film) 3558, 
2956, 2930, 2887, 2858, 171
TBSO
O
OEt
112
5, 1642, 1472, 1464, 1405, 1389, 1363, 1306, 1258, 
1176, 1098, 1029, 1007, -1
+
947, 839, 778, 679, 651 cm ; MS (ESI) calculated for 
: 267.2, found 267.1. 
A flame-dried 1 L round bottom flask equipped with stir bar and 
addition funnel was charged with ethyl acrylate 112 (15.0 g, 61.4 
mmol) in Et2O (500 mL).  The solution was cooled to -78 °C in an acetone/dry ice 
bath, and DIBAL (1 M in heptanes, 180 mL, 184 mmol) was added dropwise.  After 
two hours the reaction mixture was quenched with a saturated aqueous solution of 
Rochelle’s salt, diluted with EtOAc, and allowed to warm to room temperature.  After 
stirring over night, the organic layer was separated, and the aqueous solution 
C12H24O3Si [M+Na]
TBSO OH
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extracted three times with EtOAc.  The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo to provide 12.5 g (100%) of mono-protected bis-
allylic alcohol 119 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 5.079 (dd, J = 7.2 
Hz, 0.8 Hz, 2 H), 4.227 (s, 2 H), 4.156 (d, J = 5.6 Hz, 2 H), 1.905 (t, J = 6.4 Hz, 1 H), 
0.891 (d, J = 2.8 Hz, 9 H), 0.072 (d, J = 2.4 Hz, 6 H); 13C NMR (100 MHz, CDCl3) δ 
147.4, 110.7, 64.8, 64.1, 25.8, 25.6 (2), 18.2, -5.5; IR (film) 3431, 2956, 2930, 2896, 
2858, 1715, 1642, 1472, 1388,
; MS (ESI) calculated for C +
, 
2856, 1471, 1437, 1390, 1362, 1256, 1158, 1120, 1090, 1007, 910, 838, 777, 721, 
695, 669, 542 cm-1; MS (ESI)- calculated for C10H21IOSi [M-H]-: 311.0, found 311.2. 
 
 1306, 1259, 1176, 1096, 1029, 947, 838, 777, 679 
10H22O2Si [M+Na] : 225.1, found 225.1. 
To a flame-dried 2 L round bottom flask containing a solution of 
alcohol 119 in THF (600 mL) at 0 °C were successively added 
imidazole (7.00 g, 103 mmol), triphenylphosphine (27.0 g, 103 mmol), and I2 (26.0 g, 
103 mmol).  After 20 minutes, the reaction was diluted with hexanes (300 mL) and 
filtered through a bed of celite and rinsed thoroughly with hexanes.  The filtrate was 
concentrated in vacuo, and the resulting residue was diluted with hexanes and 
filtered through celite a second time.  The filtrate was dried of Na2SO4 and 
concentrated in vacuo to give 21.4 g of allyl iodide 122 (80%), containing a minimal 
amount of triphenylphosphine, as a pale yellow oil which was immediately brought 
on to the following alkylation reaction: 1H NMR (500 MHz, CDCl3) δ 5.288 (s, 1 H), 
5.170 (s, 1 H), 4.281 (s, 2 H), 3.928 (s, 2 H), 0.895 (s, 9 H), 0.078 (s, 6 H); 13C NMR 
(100 MHz, CDCl3) δ 145.9, 113.2, 63.9, 25.9, 18.3, 5.4, -5.4; IR (film) 2954, 2928
TBSO
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NaHMDS (0.80 M in THF/PhCH3, 0.61 mL, 0.49 mmol) was 
added to a flame-dried 25 mL round bottom flask, and diluted 
with THF (1 mL).  The solution was cooled to -78 °C in an 
acetone/dry ice bath.  Glycolylimide 98 (100 mg, 0.33 mmol) 
in THF (1 mL) was added dropwise via syringe, and the resultant enolate solution 
was stirred at -78 °C for one hour.  Iodide 122 (300 mg, 0.98 mmol) in THF (0.5 mL) 
was added dropwise via syringe, and the reaction mixture was stirred at -78 °C for 
an additional five hours, and subsequently quenched with saturated NH4Cl.  The 
organic layer was separated, and the aqueous solution extracted three times with 
CH2Cl2.  The organic layers were combined, dried over Na2SO4, and concentrated in 
vacuo.  Flash column chromatography (0% to 30% EtOAc/hexanes) provided 116 
mg (80%) of alkylation product 125 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 
7.034 (AB, JAB = 8.8 Hz, Δν = 158.0 Hz, 4 H), 5.227 (q, J = 4.4 Hz, 1 H), 5.173 (s, 1 
H), 4.999 (s, 1 H), 4.432 (m, 2 H), 4.319 (m, 1 H), 4.206-4.079 (m, 4 H), 3.774 (s, 3 
H), 2.510 (dd, J = 10.0 Hz, 4.0 Hz, 1 H), 2.366 (m, 1 H), 2.254 (m, 1 H), 0.0882 (s, 9 
H), 0.840 (dd, J = 14.8 Hz, 7.2 Hz, 6 H), 0.040 (s, 6 H); 13C NMR (100 MHz, CDCl3) 
δ 172.5, 159.4, 144.1, 130.1, 129.6, 113.6, 111.6, 76.3, 72.5, 65.7, 63.9, 58.3, 55.3, 
36.4, 28.4, 25.9, 13.4, 17.9, 14.8, -5.4; IR (film) 2956, 2929, 2856, 1781, 1710, 1613, 
1514, 1464, 1389, 1302, 1250, 1206, 1174, 1110, 1035, 903, 837, 776, 716 cm-1; 
[α]22D =   -13.98 (c 1.04, CH2Cl2); MS (ESI) calculated for C26H41NO6Si [M+Na]+: 
514.3, found 514.3. 
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A flame-dried 1 L round bottom flask equipped with stir bar and 
addition funnel was charged with glycolyloxazolidinone 125 
(13.1 g, 26.7 mmol) and methanol (2.15 mL, 53.4 mmol) 
dissolved in Et2O (270 mL).  The flask was then cooled to 0 °C in an ice bath, and 
lithium borohydride (2.0 M in THF, 27.0 mL, 53.4 mmol) was added dropwise via 
addition funnel.  The solution was subsequently stirred at -20 °C in a chemical 
refrigerator for three hours, after which Rochelle’s salt was added.  After stirring 
another hour at room temperature, the organic layer was separated, and the 
aqueous solution extracted three times with EtOAc.  The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo.  Flash column 
chromatography (25% EtOAc/hexanes) provided 9.04 g (92%) of alcohol 127 as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.054 (AB, JAB = 6.4 Hz, Δν = 146.0 Hz, 4 
H), 5.107 (s, 1 H), 4.902 (s, 1 H), 4.602 (AB, JAB = 11.2 Hz, Δν = 37.6 Hz, 2 H), 
4.066 (s, 2 H), 3.785 (s, 3 H), 3.660 (m, 2 H), 3.500 (m, 1 H), 2.400 (dd, J = 9.2 Hz, 
5.2 Hz, 1 H), 2.213 (dd, J = 7.2 Hz, 6.8 Hz, 1 H), 1.970 (t, J = 6.0 Hz, 1 H), 0.886 (s, 
9 H), 0.043 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 159.3, 144.9, 130.4, 129.4, 113.9, 
111.9, 78.1, 71.2, 66.3, 64.1, 55.3, 34.4, 24.9, 18.4, -5.4; IR (film) 3437, 2954, 2929, 
2856, 1613, 1514, 1464, 1303, 1250, 1174, 1084, 1038, 900, 837, 777 cm-1; [α]20D =  
+3.02 (c 1.29, CH2Cl2); MS (ESI) calculated for C20H34O4Si [M+Na]+: 389.2, found 
389.2. 
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To a flame-dried three-neck 500 mL round bottom flask equipped 
with stir bar, low temperature thermometer, and an addition 
funnel, was added oxalyl chloride (2.0 M in CH2Cl2, 18.5 mL, 37.0 
O
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mmol).  After dissolution in CH2Cl2 (125 mL), the solution was cooled to -78 °C in an 
acetone/dry ice bath, and DMSO (3.85 mL, 54.3 mmol) in CH2Cl2 (65 mL) was 
added dropwise via addition funnel.  After stirring 15 minutes, alcohol 127 (9.04 g, 
24.7 mmol) in CH2Cl2 (65 mL) was added dropwise via addition funnel.  Fifteen 
minutes following the addition, neat NEt3 (21.0 mL, 148 mmol) was added dropwise 
at -78 °C via addition funnel.  After stirring another 15 minutes at this temperature, 
the reaction was allowed to warm slowly over 30 minutes to room temperature, and 
quenched with saturated NH4Cl.  The organic layer was separated, and the aqueous 
solution extracted three times with CH2Cl2.  The organic layers were combined, dried 
over Na2SO4, and concentrated in vacuo.  After flash column chromatography (15% 
EtOAc/hexanes) aldehyde 252 was immediately brought on to the ensuing 
olefination assuming 100% yield: 1H NMR (400 MHz, CDCl3) δ 9.592 (d, J = 2.0 Hz, 
1 H), 7.050 (AB, JAB = 8.8, Δν = 145.6 Hz, 4 H), 5.128 (s, 1 H), 4.917 (s, 1 H), 4.526 
(AB, JAB = 11.2 Hz, 19.6 Hz, 2 H), 4.052 (s, 2 H), 3.899 (m, 1 H), 3.786 (s, 3 H), 
2.445 (dd, J = 9.6 Hz, 5.2 Hz, 1 H), 2.362 (dd, J = 8.0 Hz, 6.8 Hz, 1 H), 0.882 (s, 9 
H), 0.028 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 202.9, 159.6, 143.4, 129.7, 129.3, 
113.9, 112.6, 82.0, 72.3, 66.0, 55.3, 33.6, 25.9, 18.3, -5.4; IR (film) 2957, 2929, 
2856, 1733, 1613, 1514, 1464, 1303, 1251, 1174, 1110, 1036, 837, 777 cm-1; [α]25D = 
-5.00 (c 1.45, CH2Cl2); MS (ESI) calculated for C20H32O4Si [M+H]+: 365.2, found 
365.2. 
Methyl triphenylphosphonium bromide (35.2 g, 98.6 mmol) was 
dried via azeotrope in toluene (150 mL x 3) in a flame-dried 500 
mL round bottom flask equipped with a Dean-Stark trap.  Upon 
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cooling to room temperature, the salt was redissolved in THF (60 mL), and 
potassium t-butoxide (95%, 8.74 g, 74.0 mmol) in THF (60 mL) was added via 
cannula.  The canary yellow suspension stirred at room temperature for an hour, 
after which aldehyde 252 (see above) in THF (50 mL) was added via cannula.  After 
stirring at room temperature for 12 hours, the yellow reaction mixture was quenched 
with H2O.  After dilution with EtOAc, the organic layer was separated, and the 
aqueous solution extracted three times with EtOAc.  The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo.  Flash column 
chromatography (0% to 10% EtOAc/hexanes) provided 7.83 g (88% over two steps) 
of olefin 222 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.034 (AB, JAB = 8.8 Hz, 
Δν = 143.6 Hz, 4 H), 5.719 (m, 1 H), 5.221-5.177 (m, 2 H), 5.090 (s, 1 H), 4.864 (s, 1 
H), 4.383 (AB, JAB = 11.6 Hz, Δν = 80.4 Hz, 2 H), 4.037 (s, 2 H), 3.885 (q, J = 7.2 
Hz, 1 H), 3.779 (s, 3 H), 2.350 (dd, J = 7.2 Hz, 6.8 Hz, 1 H), 2.227 (dd, J = 8.4 Hz, 
6.0 Hz, 1 H), 0.886 (s, 9 H), 0.022 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 159.1, 
145.1, 138.7, 130.8, 129.3, 117.0, 113.8, 111.1, 79.2, 77.2, 69.9, 66.2, 55.3, 39.4, 
26.0, 25.9, 18.4, -5.4; IR (film) 2954, 2930, 1613, 1514, 1463, 1250, 1082, 1039, 
837, 776, 669 cm-1; [α]23D = -13.55 (c 1.95, CH2Cl2); MS (ESI) calculated for 
C21H34O3Si [M+Na]+: 385.2, found 385.3. 
Protected allyl alcohol 222 (1.17 g, 3.22 mmol) was dissolved in 
THF (30 mL) in a 100 mL round bottom flask.  TBAF (1 M in THF, 
9.66 mL, 9.66 mmol) was added via syringe, and the reaction was 
stirred at room temperature for one hour.  The solution was concentrated in vacuo 
and purified by flash column chromatography (30% EtOAc/hexanes) to give 800 mg 
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(100%) of alcohol 228 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.027 (AB, JAB 
= 8.8 Hz, Δν = 137.6 Hz, 4 H), 5.746 (m, 1 H), 5.256-5.213 (m, 2 H), 5.041 (s, 1 H), 
4.875 (s, 1 H), 4.386 (AB, JAB = 11.2 Hz, 94.0 Hz, 2 H), 4.011 (d, J = 4.0 Hz, 2 H), 
3.882 (q, J = 7.6 Hz, 4.8 Hz, 1 H), 3.773 (s, 3 H), 3.279 (s, 1 H), 2.365 (m, 2 H); 13C 
NMR (100 MHz, CDCl3) δ 159.3, 145.8, 138.1, 130.0, 129.5, 117.5, 113.9, 113.5, 
80.0, 70.1, 66.5, 55.3, 40.1; IR (film) 3416, 3075, 2934, 2907, 2861, 2838, 1613, 
1514, 1464, 1302, 1248, 1174, 1035, 927, 902, 822 cm-1; [α]20D = -34.35 (c 0.89, 
CH2Cl2); MS (ESI) calculated for C15H20O3 [M+Na]+: 271.1, found 271.1. 
To a flame-dried three-neck 500 mL round bottom flask equipped with  
stir bar, low temperature thermometer, and an addition funnel, was 
added oxalyl chloride (2.0 M in CH2Cl2, 15.0 mL, 30.1 mmol).  After 
dissolution in CH2Cl2 (100 mL), the solution was cooled to -78 °C in an acetone/dry 
ice bath, and DMSO (3.10 mL, 44.1 mmol) in CH2Cl2 (50 mL) was added dropwise 
via addition funnel.  After stirring 15 minutes, alcohol 228 (4.98 g, 20.1 mmol) in 
CH2Cl2 (50 mL) was added dropwise via addition funnel.  Fifteen minutes following 
the addition, neat NEt3 (17.0 mL, 120 mmol) was added dropwise at -78 °C via 
addition funnel.  After stirring another 15 minutes at this temperature, the reaction 
was allowed to warm slowly over 30 minutes to room temperature, and quenched 
with saturated NH4Cl.  The organic layer was separated, and the aqueous solution 
extracted three times with CH2Cl2.  The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo.  Flash column chromatography (15% 
EtOAc/hexanes) provided 4.80 g (97%) of aldehyde 253 as a colorless oil: 1H NMR 
(500 MHz, CDCl3) δ 9.468 (s, 1 H), 7.010 (AB, JAB = 8.5 Hz, Δν = 166.5 Hz, 4 H), 
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6.132 (s, 1 H), 6.043 (s, 1 H), 5.694 (m, 1 H), 5.212-5.167 (m, 2 H), 4.356 (AB, JAB = 
11.5 Hz, Δν = 107.5 Hz, 2 H), 3.892 (q, J = 8.0 Hz, 5.5 Hz, 1 H), 3.777 (s, 3 H), 
2.541 (dd, J = 7.5 Hz, 6.5 Hz, 1 H), 2.473 (dd, J = 6.5 Hz, 5.5 Hz, 1 H); 13C NMR 
(125 MHz, CDCl3) δ 194.4 (2), 159.0, 146.1, 138.0, 136.7, 130.4, 129.3, 117.6, 
113.7, 78.1, 69.9, 55.2, 34.0; IR (film) 3418, 1686, 1614, 1514, 1248, 1174, f1036, 
930, 822, 750 cm-1; [α]20D = -14.57 (c 0.33, CH2Cl2); MS (ESI) calculated for 
C15H18O3 [M+Na]+: 269.1, found 269.1. 
A 500 mL round bottom flask was charged with aldehyde 253 (4.80 
g, 19.5 mmol), which was dissolved in 200 mL of a 4:1 t-BuOH:H2O 
solution.  NaH2PO4•H2O (8.08 g, 58.6 mmol), 2-methyl-2-butene 
(19.0 mL, 176 mmol), and NaClO2 (80%, 13.2 g, 117 mmol) were added 
successively, and the resultant clear yellow solution was allowed to stir at room 
temperature over 12 hours.  The reaction mixture was quenched with a saturated 
solution of NH4Cl.  After dilution with EtOAc, the organic layer was separated, and 
the aqueous solution extracted three times with EtOAc.  The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo.  Flash column 
chromatography (30% to 50% EtOAc/hexanes) provided 5.07 g (88% over two 
steps) of acrylate 205 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.006 (AB, JAB 
= 8.4 Hz, Δν = 140.0 Hz, 4 H), 6.343 (s, 1 H), 5.776-5.697 (m, 2 H), 5.242-5.2011 
(m, 2 H), 4.399 (AB, JAB = 11.6 Hz, Δν = 82.8 Hz, 2 H), 3.963 (q, J = 7.6 Hz, 6.0 Hz, 
1 H), 3.758 (s, 3 H), 2.616 (dd, J = 8.0 Hz, 6.0 Hz, 1 H), 2.507 (dd, J = 8.4 Hz, 5.6 
Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 172.3, 159.0, 137.9, 136.3, 130.3, 129.8, 
129.3, 117.6, 113.7, 78.6, 70.0, 55.2, 37.8; IR (film) 2934, 1695, 1613, 1514, 1442, 
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1303, 1248, 1174, 1076, 1036, 931, 823 cm-1; [α]19D = -26.09 (c 1.32, CH2Cl2); MS 
(ESI) calculated for C15H18O4 [M+Na]+: 285.1, found 285.1. 
To a solution 1 L round bottom flask containing L-ethyl lactate 
(14.4 mL, 127 mmol) in CH2Cl2 (400 mL) was added imidazole 
(22.0 g, 317 mmol) and TBDPSCl (40.0 mL, 152 mmol), 
successively.  The reaction mixture was stirred at room temperature for one hour 
after which it was quenched with saturated NaHCO3.  The organic layer was 
separated, and the aqueous solution extracted three times with CH2Cl2.  The organic 
layers were combined, dried over Na2SO4, and concentrated in vacuo.  Further 
drying under low pressure provided 45.3 g (100%) of acrylate 149 as a colorless oil: 
1H NMR (400 MHz, CDCl3) δ 7.545 (t, J = 8.4 Hz, 4 H), 7.268 (m, 6 H), 4.133 (q, J = 
6.8 Hz, 1 H), 3.882 (q, J = 7.2 Hz, 2 H), 1.239 (d, J = 6.8 Hz, 3 H), 1.008 (t, J = 7.2 
Hz, 3 H), 0.964 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ173.7, 135.9, 135.7, 133.6, 
133.2, 129.7, 127.6, 127.5, 68.9, 60.5, 26.8, 21.2, 19.2, 14.0; IR (film) 3071, 2959, 
2932, 2893, 2852, 1753, 1734, 1474, 1427, 1373, 1273, 1196, 1146, 1120, 1061, 
1022, 974, 824, 739, 700, 611 cm-1; [α]20D = -44.36 (c 1.00, CH2Cl2); MS (ESI) 
calculated for C21H28O3Si [M+Na]+: 379.2, found 379.2. 
TBDPSO
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A 2 L flame-dried round bottom flask equipped with addition funnel 
and charged with a solution of acrylate 149 (22.7 g, 63.5 mmol) in 
Et2O (700 mL), was cooled to -78 °C in an acetone/dry ice bath.  
DIBAL (1 M in heptanes, 132 mL, 132 mmol) was added dropwise via addition 
funnel, and after 30 minutes of stirring at that same temperature following the 
addition, the reaction was quenched with saturated aqueous solution of Rochelle’s 
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salt, diluted with EtOAc, and allowed to warm to room temperature.  After three 
hours of stirring at room temperature, the quenched mixture was filter through celite, 
dried over MgSO4, and filtered a second time through celite.  Concentration in vacuo 
provided 20.0 g (100%) of aldehyde 150 as a colorless oil: 1H NMR (400 MHz, 
CDCl3) δ 9.625 (d, J = 1.6 Hz, 1 H), 7.690-7.520 (m, 4 H), 7.444-7.357 (m, 6 H), 
4.091 (q, J = 6.8 Hz, 1 H), 1.217 (d, J = 7.2 Hz, 3 H), 1.108 (s, 9 H); 13C NMR (100 
MHz, CDCl3) 203.8, 135.7 (2), 133.3 (2), 130.0, 129.9, 127.8, 127.7, 74.4, 26.8, 
19.1, 18.4; IR (film) 3071, 3050, 2859, 2932, 2891, 2857, 1736, 1472, 1427, 1113, 
964, 822, 741, 709, 611  cm-1; [α]19D = -8.93 (c 1.78, CH2Cl2); MS (ESI) calculated for 
C19H24O2Si [M+K]+: 351.2, found 351.1. 
Aldehyde 150 (20.0 g, 63.5 mmol) was dissolved in CH2Cl2 
(600 mL) in a 1 L flame-dried round bottom flask.  Ethyl-
(triphenylphosphoranylidine)acetate (63 g, 181 mmol) was 
added, and the solution was allowed to stir at room temperature for two hours, after 
which it was quenched with H2O.  The organic layer was separated, and the 
aqueous solution extracted three times with CH2Cl2.  The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo.  Flash column 
chromatography (5% to 10% EtOAc/hexanes) provided 23.1 g (95%) of α,β-
unsaturated ester 151 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.652 (dd, J = 
22.8 Hz, 6.4 Hz, 4 H), 7.419-7.314 (m, 6 H), 6.893 (dd, J = 11.2 Hz, 4.4 Hz, 1 H), 
6.007 (dd, J = 14.0 Hz, 1.6 Hz, 1 H), 4.454 (m, 1 H), 4.185 (m, 2 H), 1,286 (t, J = 7.2 
Hz, 3 H), 1.118 (d, J = 6.8 Hz, 3 H), 1.076 (s, 9 H); 13C NMR (100 MHz, CDCl3) 
166.8, 151.5, 135.8, 135.7, 134.0, 133.4, 129.7, 127.6 (2), 119.1, 68.6, 60.3, 26.9, 
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23.2, 19.2, 14.3; IR (film) 3071, 3050, 2961, 2932, 2893, 2852, 1700, 1659, 1472, 
1427, 1368, 1294, 1373, 1152, 1103, 1090, 1055, 978, 924, 822, 741, 700, 615 cm-1; 
[α]19D = -9.07 (c 1.78, CH2Cl2); MS (ESI) calculated for C23H30O3Si [M+Na]+: 405.2, 
found 405.3. 
A flame-dried 1 L round bottom flask equipped with stir bar 
and addition funnel was charged with α,β-unsaturated ester 
151 (10.1 g, 26.4 mmol) in Et2O (250 mL).  The solution was cooled to -78 °C in an 
acetone/dry ice bath, and DIBAL (1 M in heptanes, 80.0 mL, 79.2 mmol) was added 
dropwise via addition funnel.  After the addition, the solution was warmed slowly to 
room temperature over two hours, and was subsequently quenched with a saturated 
aqueous solution of Rochelle’s salt and diluted with EtOAc.  The organic layer was 
separated after two hours, and the aqueous solution was extracted three times with 
EtOAc.  The organic layers were combined, dried over Na2SO4, and concentrated in 
vacuo, Flash column chromatography (20% to 40% EtOAc/hexanes) provided 8.93 g 
(99%) of allyl alcohol 152 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.653 (t, J 
= 6.8 Hz, 4 H), 7.421-7.327 (m, 6 H), 5.645 (dd, J = 10.0 Hz, 5.6 Hz, 1 H), 5.545 (dt, 
J = 10.4 Hz, 5.2 Hz, 1 H), 4.338 (m, 1 H), 3.983 (d, J = 5.2 Hz, 2 H), 1.164 (d, J = 6.4 
Hz, 3 H), 1.062 (s, 9 H); 13C NMR (100 MHz, CDCl3) 136.0 (3), 134.3, 129.5 (2), 
127.7, 127.5, 127.4, 69.6, 63.1, 27.0, 24.2, 19.2; IR (film) 3341, 2962, 2930, 2857, 
1472, 1427, 1147, 1112, 1078, 998, 970, 823, 739, 702, 612, 507 cm-1; [α]21D = -
21.21 (c 2.09, CH2Cl2); MS (ESI) calculated for C21H28O2Si [M+Na]+: 363.2, found 
363.2. 
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Sodium hydride (60% dispersion in mineral oil, 3.12 g, 
78.1 mmol) was washed three times with hexanes (50 
mL) under argon in a flame-dried 250 mL round bottom flask.  The flask was 
subsequently charged with THF (40 mL), and the septum replaced with an addition 
funnel.  The resulting suspension was cooled to 0 °C in an ice water bath, and 
alcohol 152 (17.7 g, 52.0 mmol) in DMF (10 mL) was added dropwise via addition 
funnel.  After stirring at 0 °C for 30 minutes, neat allyl bromide (5.40 mL, 62.4 mmol) 
was added dropwise via addition funnel.  The solution remained stirring at 0 °C for 
20 minutes, and was quenched slowly with H2O.  EtOAc was added, the organic 
layer was separated, and the aqueous solution was extracted three times with 
EtOAc.  The organic layers were combined, dried over Na2SO4, and concentrated in 
vacuo.  Flash column chromatography (5% EtOAc/hexanes) provided 19.8 g (100%) 
of bis-allylic alcohol 153 as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.706-7.627 
(m, 4 H), 7.418-7.352 (m, 6 H), 5.916 (m, 1 H), 5.756 (dd, J = 9.6 Hz, 5.6 Hz, 1 H), 
5.606 (dt, J = 5.6 Hz, 4.0 Hz, 1 H), 5.284 (dd, J = 15.6 Hz, 1.6 Hz, 1 H), 5.197 (dd, J 
= 9.2 Hz, 1.2 Hz, 1 H), 4.364 (m, 1 H), 3.961 (d, J = 5.6 Hz, 4 H), 1.168 (d, J = 6.4 
Hz, 3 H), 1.101, (s, 9 H); 13C NMR (100 MHz, CDCl3) 137.3, 135.8 (2), 135.5, 134.8, 
134.4, 134.1, 129.5 (2), 127.5, 127.4 (2), 125.1, 116.8, 70.7, 70.1, 69.5, 29.7, 27.0, 
26.8, 24.2, 19.2; IR (film) 3071, 2930, 2857, 1472, 1428, 1363, 1112, 823, 740, 702, 
612, 506 cm-1; [α]22D = -27.76 (c 2.26, CH2Cl2); MS (ESI) calculated for C24H32O2Si 
[M+Na]+: 403.2, found 403.2. 
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Protected bis-allylic alcohol 153 (9.80 g, 25.7 mmol) was 
dissolved in THF (30 mL) in a 100 mL round bottom flask.  
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The solution was cooled to 0 °C in an ice water bath, and TBAF (1 M in THF, 77.2 
mL, 77.2 mmol) was added via syringe.  The reaction was allowed to warm slowly to 
room temperature, and was stirred for an additional 12 hours.  The solution was 
concentrated in vacuo and quickly removed from the reaction byproducts over a 
small silica plug (30% to 50% EtOAc/hexanes).  Distillation under reduced pressure 
(bp = 75 °C, 7 mm Hg) provided 2.92 g (80%) of alcohol 154 as a clear oil: 1H NMR 
(400 MHz, CDCl3) δ 5.895 (m, 1 H), 5.757-5.722 (m, 2 H), 5.246 (dd, J = 16.4 Hz, 
0.8 Hz, 1 H), 5.155 (d, J = 10.4 Hz, 1 H), 4.299 (m, 1 H), 3.945 (m, 4 H), 1.850 (s, 1 
H), 1.241 (d, J = 6.4 Hz, 3 H); 13C NMR (100 MHz, CDCl3) 137.1, 134.6, 126.0, 
117.1, 71.2, 70.0, 68.1, 23.1; IR (film) 3389, 2973, 2856, 1120, 1063, 971, 927 cm-1; 
[α]22D = +2.08 (c 1.44, CH2Cl2); MS (APCI) calculated for C8H14O2 [M-H]-: 141.1, 
found 141.0. 
A 250 mL flame-dried round bottom flask charged with 
THF (100 mL), acrylate 205 (2.50 g, 9.53 mmol) and 
NEt3 (1.73 mL, 12.4 mmol) was cooled to -78 °C in an 
acetone/dry ice bath.  Pivaloyl chloride (1.29 mL, 10.5 mmol) was subsequently 
added dropwise via syringe, and the solution was warmed to -20 °C, where the 
temperature was maintained for 2.5 hours. The white cloudy suspension was 
concentrated in vacuo, and filtered through a cotton plug with dry THF, and 
concentrated once more.  The resultant oil was dried via azeotrope in toluene (25 
mL x 3).  After dissolution in toluene (30 mL), alcohol 154 (1.50 g, 10.5 mmol) was 
added, followed by DMAP (2.33 g, 19.0 mmol), and the solution was allowed to stir 
at 60 °C for 3 hours.  The reaction mixture was quenched with 0.1 N HCl and diluted 
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with EtOAc.  The organic layer was separated, and the aqueous solution extracted 
three times with EtOAc.  The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo.  Flash column chromatography (0% to 30% EtOAc/hexanes) 
provided 2.05 g (68%) of tetraene 230 as a colorless oil: 1H NMR (400 MHz, CDCl3) 
δ 7.010 (AB, JAB = 8.0 Hz, Δν = 138.8 Hz, 4 H), 6.193 (s, 1 H), 5.871 (m, 1 H), 
5.756-5.657 (m, 3 H), 5.569 (s, 1 H), 5.373 (m, 1 H), 5.275-5.148 (m, 4 H), 4.370 
(AB, JAB = 11.6 Hz, Δν = 77.6 Hz, 2 H), 3.941 (m, 5 H), 3.766 (s, 3 H), 2.616 (dd, J = 
7.2 Hz, 6.8 Hz, 1 H), 2.494 (dd, J = 8.0 Hz, 5.6 Hz, 1 H), 1.293 (d, J = 6.4 Hz, 3 H); 
13C NMR (100 MHz, CDCl3) 166.2, 159.0, 138.2, 137.1, 134.6, 132.0, 130.7, 129.2, 
128.1, 127.3, 117.3, 117.0, 113.7, 78.7, 71.2, 70.5, 69.9, 69.8, 38.2, 20.1; IR (film) 
2935, 1718, 1611, 1514, 1250, 1172, 1036 cm-1; [α]20D = -20.20 (c 0.75, CH2Cl2); MS 
(ESI) calculated for C23H30O5 [M+H]+: 387.2, found 387.3. 
Ester 230 (120 mg, 0.310 mmol) was dissolved in toluene (150 mL) 
in a 500 mL flame-dried three neck round bottom flask equipped 
with stir bar, reflux condenser, long argon inlet needle, and outlet 
needle.  The inlet needle was placed into the solution, and argon was vigorously 
bubbled through the solvent at reflux.  After degassing via reflux for one hour, 136 
(40.0 mg, 0.047 mmol) was added over 16 hours via syringe pump addition.  After 
an additional 12 hours, the solution was allowed to sit open to air at room 
temperature.  The solution was concentrated in vacuo and purified by flash column 
chromatography (0% to 40 EtOAc/hexanes) to give 62 mg (69%) of butenolide 200 
as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.013 (AB, JAB = 8.4 Hz, Δν = 134.0 
Hz, 4 H), 7.052 (s, 1 H), 5.779-5.691 (m, 1 H), 5.267 (dd, J = 4.4 Hz, 1.2 Hz, 1 H), 
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5.230 (s, 1 H), 4.950 (dq, J = 5.2 Hz, 1.6 Hz, 1 H), 4.375 (AB, JAB = 11.2 Hz, Δν = 
84.8 Hz, 2 H), 4.031 (q, J = 7.6 Hz, 5.2 Hz, 1 H), 3.773 (s, 3 H), 2.565 (dd, J = 8.0 
Hz, 7.2 Hz, 1 H), 2.480 (dd, J = 10.0 Hz, 5.2 Hz, 1 H), 1.348 (d, J = 6.8 Hz, 3 H); 13C 
NMR (100 MHz, CDCl3) 173.7, 159.2, 151.7, 137.8, 130.4, 130.1, 129.4, 117.9, 
113.8, 77.7, 77.4, 70.0, 55.3, 31.2, 19.0; IR (film) 1752, 1613, 1514, 1319, 1248, 
1078, 1029, 822 cm-1; [α]23D = +6.23 (c 0.90, CH2Cl2); MS (ESI) calculated for 
C17H20O4 [M+H]+: 311.1, found 311.2. 
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